{
  "name" : "dacemirror.sci-hub.se_journal-article_ac04c2dbc55acce6267efeea8a12dfa5_yan2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "A Safe-by-Design Strategy towards Safer Nanomaterials in Nanomedicines",
    "authors" : [ "Liang Yan", "Feng Zhao", "Jing Wang", "Yan Zu", "Zhanjun Gu", "Yuliang Zhao" ],
    "emails" : [ "zjgu@ihep.ac.cn;", "zhaoyl@nanoctr.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1805391 (1 of 33) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de"
    }, {
      "heading" : "A Safe-by-Design Strategy towards Safer Nanomaterials",
      "text" : "in Nanomedicines\nLiang Yan, Feng Zhao, Jing Wang, Yan Zu, Zhanjun Gu,* and Yuliang Zhao*\nDr. L. Yan, Dr. F. Zhao, Dr. J. Wang, Dr. Y. Zu, Prof. Z. Gu, Prof. Y. Zhao CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety Nanoscience National Center for Nanoscience and Technology of China Beijing 100190, China E-mail: zjgu@ihep.ac.cn; zhaoyl@nanoctr.cn Dr. L. Yan, Dr. F. Zhao, Dr. Y. Zu, Prof. Z. Gu, Prof. Y. Zhao CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety Institute of High Energy Physics Chinese Academy of Sciences Beijing 100049, China Prof. Z. Gu, Prof. Y. Zhao College of Materials Science and Optoelectronic Technology University of Chinese Academy of Sciences Beijing 100049, China Prof. Y. Zhao CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing 100190, China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201805391.\nDOI: 10.1002/adma.201805391\nthe fruitful research driven by innovators across various disciplines, these solutions have exhibited great potential in addressing the hurdles in current pharmaceutics and have given birth to an exciting era of nanomedicine. In the early 1980s, liposomes were applied to deliver hydrophobic drugs such as doxorubicin and then exploited for cancer therapy with fewer side effects, which largely resulted from the increased drug deposition due to the enhanced permeability and retention (EPR) effect.[11–13] From then on, substantial effort is being devoted to developing various types of nanomedicines with the broad potential applications ranging from drug delivery and in vitro diagnostics to in vivo therapies and active implants.[14–16] Examples include lipid micelles[17] and mesoporous silica nanoparticles (NPs)[18]\nas nanocarriers for drug delivery, quantum dots (QDs),[19] superparamagnetic iron oxide NPs,[20,21] upconversion NPs,[22] and Bi2S3 NPs[23] as contrast agents for bioimaging, gold nanoclusters,[24,25] polymeric nanostructures,[26] and two-dimensional transition metal dichalcogenides[27] as therapeutic agents for cancer treatment, and carbon-based nanomaterials like carbon nanotubes (CNTs)[28] and graphene[29] as stents and implants for tissue regeneration and repair. According to a bibliometric analysis, the number of publication in nanomedicine has witnessed an exponential surge over the past decades, rising from several articles per year in the late 1990s to more than 8000 articles in the year 2017[30] (Figure 1a). A search in the European Patent Office database results in 312 patent filings in the nanomedicine sector in the year 2017, compared to only 1 in 1996[31] (Figure 1b). Remarkably, drug delivery is the dominant research field with a share of 82.0% of the scientific papers and 53.3% of the patents, showing an advanced commercialization status (Figure 1c). Comparison among countries indicates that the United States is at the forefront of research with a share of 53.0%[32] (Figure 1d).\nDespite that the marriage of nanotechnology and medicine has yielded an offspring capable of bringing momentous advance in the fight against diseases, the widespread use of nanomaterials in medicine has arisen over growing concerns about their possible adverse health effects in humans.[33–36] In previous in vitro studies, CdSe QDs, a bioimaging agent, displayed apparent hepatocyte toxicity due to the breakdown of their structures and the subsequent leakage of cadmium ions.[37] Besides, other reports have suggested that CNTs could induce significant cellular responses like inflammation and gene damage in several\nThe marriage of nanotechnology and medicine offers new opportunities to fight against human diseases. Benefiting from their unique optical, thermal, magnetic, or redox properties, a wide range of nanomaterials have shown potential in applications such as diagnosis, drug delivery, or tissue repair and regeneration. Despite the considerable success achieved over the past decades, the newly emerging nanomedicines still suffer from an incomplete understanding of their safety risks, and of the relationships between their physicochemical characteristics and safety profiles. Herein, the most important categories of nanomaterials with clinical potential and their toxicological mechanisms are summarized, and then, based on this available information, an overview of the principles in developing safe-by-design nanomaterials for medical applications and of the recent progress in this field is provided. These principles may serve as a starting point to guide the development of more effective safe-by-design strategies and to help identify the major knowledge and skill gaps.\nClinical Nanomaterials"
    }, {
      "heading" : "1. Introduction",
      "text" : "In the past few decades since its emergence, nanotechnology has offered a variety of innovative solutions that enable specific medical interventions at the molecular scale for prevention, diagnosis, and treatment of diseases as well as repair of tissues by taking advantage of nanomaterials with unique optical, thermal, magnetic, or redox properties.[1–10] Thanks to\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (2 of 33)\ncell types, and even cause a synergistic toxicity in the presence of other pollutants such as Zn ions, although the results on this issue have been conflicting.[38–42] In the vision of the increasing preclinical and clinical use of newly designed medical nanomaterials, it is rather important that these nanomaterials are safe enough, while simultaneously maintaining their parental nanomedical functions during their whole life-cycles. We suggest that, to develop efficient approaches toward this goal, knowledge and methodology in the following aspects are required."
    }, {
      "heading" : "1.1. Measurement of the Physicochemical Properties of Nanomaterials",
      "text" : "Compared to bulk materials, many physicochemical properties of nanomaterials such as surface area and solubility are related specifically to their size and structure. For example, different carbon nanoallotropes with the same elemental composition, such as fullerenes, CNTs, and graphene, possess different sizes and structures or could be chemically functionalized with different functional moieties[43]; gold nanorods and nanostars exhibit stronger near-infrared (NIR) absorption than counterparts of the same composition in nanoparticle and bulk form.[44,45] Moreover, small variations in these properties may induce dramatic changes in critical secondary properties including toxicity profiles and nanomedical functions.[46] Once in touch with biological microenvironments like blood, nanomaterials immediately interact with various biomolecules, leading to further changes of their physicochemical properties like aggregation/ agglomeration states. Considering all these possible variations, there is a substantial need for in situ and real-time characterization of nanomaterials under clinically relevant conditions."
    }, {
      "heading" : "1.2. Quantification of the In Vivo Trafficking of Nanomedicine",
      "text" : "Absorption, distribution, metabolism, and excretion of nanomedicines are the four fundamental biological processes following their intentional or unintentional exposure.[47,48] In vivo quantification of the structure, composition, spatial distribution, existent form, biological effects of nanomedicines, as well as monitoring of their dynamic transportation is critical for an accurate understanding of their pharmacokinetics profiles within the body. However, nanomedicines are far more complicated than the conventional chemical drugs in terms of structure, composition, and aggregation state, thus rendering almost all of conventional techniques inadequate for quantitative nanomedical analyses. Therefore, advanced analytical methodologies are required to construct a reliably comprehensive spectrum of the in vivo fates of nanomedicines. This issue has already been discussed previously in several of our dedicated reviews.[49,50]"
    }, {
      "heading" : "1.3. Revelation of Bio-Nano Interaction Mechanisms Relevant for Nanotoxicology",
      "text" : "It is well-accepted that the toxicity of nanomaterials is largely dominated by the bio-nano interface between their surface and the local physiological environment.[51,52] The high surface free energy of nanomaterials renders these biological interactions thermodynamically favorable, which subsequently leads to the formation of coronas on the nanosurface and to diverse intracellular biocatalytic processes that may induce serious structural and functional alterations in the adsorbed biomolecules.[53,54] In turn, such interactions often further alternate their physicochemical properties and even nanomedical functions. Given that these changes have important nanotoxicological implications, underlying the bio-physicochemical interactions at the\nLiang Yan received his B.S. degree in chemistry from Sichuan University in 2009 and his Ph.D. degree in inorganic chemistry from the Institute of High Energy Physics, Chinese Academy of Science in 2014, under the direction of Prof. Yuliang Zhao. He then joined the faculty at CAS Key Lab for Biomedical Effects of Nano-\nmaterials & Nanosafety at the Institute of High Energy Physics. His current research is focused on the design and preparation of nanostructured materials for delivery systems and cancer theranostics.\nZhanjun Gu received his B.E. degree from Huazhong University of Science and Technology in 2002 and his Ph.D. degree from the Institute of Chemistry, Chinese Academy of Science in 2007, under the direction of Prof. Jiannian Yao. He then became a postdoctoral fellow at the University of Georgia. In 2009, he joined the faculty at CAS Key Lab for\nBiomedical Effects of Nano-materials & Nanosafety of the Institute of High Energy Physics. His current research interests include nanomaterials synthesis, optical spectroscopy, and bioapplications of luminescent nanomaterials.\nYuliang Zhao is the founder of CAS Key Lab for Biomedical Effects of Nano-materials & Nanosafety, and is professor and director of National Center for Nanoscience and Technology of China. He was elected as a member of the Chinese Academy of Science in 2017. His research interests mainly include analytical chemi stry, nanotoxicology, and nanomedicine.\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (3 of 33)\nbio-nano interface is the key to mitigate the potential adverse effect of nanomaterials and then create safe nanomedicines. However, progress in this aspect is often hindered by the lack of toxicity assays appropriate for nanomaterials. More analytical techniques have therefore been developed to probe the bionano interfaces, so as to achieve measurable nanotoxicological outcomes to guide the engineering of novel nanomedicines with fewer side effects.[55–57]"
    }, {
      "heading" : "1.4. Development of Nanoinformatic Tools for Design of Safe Nanomedicine",
      "text" : "Nanoinformatics, an emerging field of nanomedicine, involves the management of data derived from study on nanomaterials and their biomedical applications, followed by the integration and analysis of such data with computational algorithms to identify important nanomedicine design parameters as guidance for computational and experimental nanomedical research.[58,59] For example, several computational models have already been developed to study the fundamental properties and biological behaviors of nanomedicines, such as drug encapsulation, delivery and release,[60,61] as well as their biological effects on the cells and tissues.[62,63] Such efforts, despite their potential and significance, still suffer from the fact that data generated from nanomedical research are excessively large in volume and conflicting in content, making it difficult to effectively browse and unambiguously\ninterpret them. Therefore, it is significant to develop nanoinformatic tools to aggregate and share the information in the field of nanomedicine with high efficiency, which facilitates the development of rational approaches to understand the fundamental nanomaterial-biological interactions and then rationalize the selection of appropriate materials for the design of safe nanomedicines with desired nanomedical functions."
    }, {
      "heading" : "1.5. Development of Nano Quantitative Structure-Activity Relationship Models for Nanomedicine",
      "text" : "Quantitative structure-activity relationship (QSAR) is a computational method that can establish the quantitative correlation between the physicochemical properties of drugs and a set of molecular descriptors derived from their structure. Since its discovery, QSAR model has been widely applied to drug design as well as the prediction of their toxicity.[64–66] Later, many studies demonstrated that the general QSAR paradigm could be further extended to nanomaterials and develop “nano-QSAR” model which can establish predictive relationship between their physicochemical properties and biological effects (both desired and undesired).[67–70] This success largely depends on the application of high-throughput techniques coupled with cluster analysis and data mining, by which a large number of biological data could be achieved and then integrated into the large-scale modeling. However, modeling nanomaterials and\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (4 of 33)\ntheir biological effects still suffers from the lack of quantitative parameters capable of characterizing their structural and chemical properties. As a result, sufficiently large robust and reliable nano-QSAR techniques would be developed to provide comprehensive information about the relationships between structure and biological effect, and finally support better informed decisions in the design of medical nanomaterials to avoid their potential adverse effects."
    }, {
      "heading" : "1.6. Development of Proactive Strategies for Safe-by-Design Nanomedicine",
      "text" : "By examining the recent literature, we notice that the studies carried out by the material research community in the past decades primarily focused on fundamental questions in the material field such as the discovery of interesting nanostructures, the synthesis and characterization of these nanostructures, and the development of nanostructure-based materials. So far, a gap between nanomaterials viewed from the perspective of material science and safe nanomedicines for biomedical application still exists. It remains necessary to address more challenging issues regarding medical nanomaterials in the biomedical perspective, such as how the properties of a given nanostructure affect its physicochemical characteristics, toxic profiles, as well as nanomedical functions, and how to develop quantitative structureactivity relationships. These would enable an effective control of nanomaterial performance through rational design, and offer powerful tools for the development of safe nanomaterials.\nIn order to minimize the potential risks of nanomedicines during the design stage in addition to downstream processes, great effort has been devoted to overcome the above described challenges.[64,71–74] Herein, we will examine the recent progress in the development of safe-by-design nanomedicines, and then provide an overview of the relevant toxicological mechanisms of biomedical nanomaterials as well as the effort to integrate such knowledge into nanomedicine design. We hope that this review will help to reveal useful strategies and principles for the safe design, synthesis, and manufacturing of nanomedicines, while simultaneously reducing the current gap in their clinical translation."
    }, {
      "heading" : "2. Recent Discoveries in Nanotoxicology and Nanomedical Implications",
      "text" : "From the viewpoint of surface chemistry, decreasing the size of nanomaterials leads to an increase in the number of atoms and crystal lattice defects on their surface, which greatly enhances their surface reactivity and facilitates bio-physicochemical interactions at the bio-nano interface.[75] This feature characteristic to nanosized structures could be useful for the construction of functional nanomaterials for many biomedical applications like tissue engineering, diagnostic assays, and therapeutic delivery systems. On the other hand, the small size and high surface energy of nanomaterials make them easier to interact with cellular components and biological systems, potentially leading to unwanted chemical/biological/toxicological reactivity within normal tissues.[76,77] It is therefore of great significance to find\nan optimal balance between nanomedical function and nanotoxicity, which represent two sides of the same coin. In this sense, below we will first discuss the major types of nanomaterials for biomedical application, and then delineate the potential mechanisms of their nanotoxicity case-by-case."
    }, {
      "heading" : "2.1. Advanced Nanomaterials for Biological Applications",
      "text" : "Nanomaterials such as liposomes and polymeric structures have long been explored as “classical” drug carriers for delivering pharmacologically active agents to the pathological sites, with many of them having been investigated in preclinical and clinical trials. Other nanomaterials with diagnostic or therapeutic implications, such as gold NPs (AuNPs), iron oxide NPs, carbon-based nanomaterials, are also attracted more and more attention as agents for imaging-guided therapy in which diagnosis and therapy are combined together (Figure 2)."
    }, {
      "heading" : "2.1.1. Liposomes",
      "text" : "Since their original description in the 1960s by Bangham, liposomes have been widely studied in both fields of nanomedicine and cosmetics, and have become the most successful drug delivery system known to date[78,79] (Figure 2a). Benefiting from their vesicular structures consisted of a lipid bilayer shell surrounding an aqueous core, liposomes can encapsulate both hydrophilic and lipophilic drugs, as well as immunostimulatory oligonucleotides, genes, peptides, and proteins, and deliver them to the pathological sites for more effective treatments with fewer side effects.[1] Encapsulating drugs into liposomes may improve their solubility, prevent their possible chemical and biological degradation during administration, and enable additional physical or chemical functionalization of the formulation with specific surface ligands and contrast agents. Such functionalized liposomal drug carriers show enhanced ability to target diseased sites and enable spatiotemporally controlled release of their payloads in response to specific exogenous (e.g., heat, magnetic field, and light) or endogenous (e.g., pH, redox potential, and enzymes) stimuli.[80–82] Based on these advantages, liposomal formulations have been exploited for imaging-guided drug delivery, and some of them such as Doxil and DaunoXome have been investigated in clinical trials or even become commercially available to patients.[83] However, once administered into the body, liposomal delivery systems are subject to multiple defense systems that recognize, neutralize and eliminate foreign liposomes, severely affecting their pharmacokinetic profiles and biodistribution.[84]"
    }, {
      "heading" : "2.1.2. Polymeric and Biomacromolecular Nanomaterials",
      "text" : "Polymeric nanomaterial-based drug delivery systems, due to their flexibility and biodegradability, have shown great potential in biomedical applications including drug delivery, diagnosis, therapeutic, and tissue engineering.[9,85–90] Many studies have demonstrated that polymeric nanomaterials like polymeric micelles, nanocapsules, nanogels, dendrimers, and polymeric hybrid NPs could be used as nanocarriers to deliver\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (5 of 33)\nwater-insoluble anticancer drugs, peptides, proteins, DNA, and RNA to the desired site of action[91–93] (Figure 2b). Similar to liposomes, polymeric nanomaterials also improve the solubility and stability of the encapsulated drugs, as well as their therapeutic effects due to a greater fraction of drug reaching the target site.[94] In addition, conjugation of polymeric nanomaterials to bioactive ligands and macromolecules endows them with superior targeting ability while at the same time reducing their systemic toxicity. Stimuli-responsive polymeric nanomaterials have also been developed, being able to rapidly change their macroscopic behaviors (e.g., shape, solubility, swelling, and dissociation) in response to light, temperature, or other disease-associated stimuli.[95] The main obstacles for the clinical application of polymeric nanomaterials include short circulation time, inadequate degradation induced by environment or enzymes, and heterogeneity of structures introduced during the synthetic processes, which may lead to inappropriate distribution of payloads and nonspecific toxicity.[96,97] Alternatively, nanomaterials based on biomacromolecules, such as assemblies of peptides and peptide derivatives, protein NPs, and DNA-based nanostructures, due to their chemical versatility, biocompatibility, and biological recognition capability, have also been extensively studied for: i) biosensors with high sensitivity, ii) nanocarriers for in vitro and in vivo drug delivery, and iii) bioscaffolds for tissue repair and regeneration.[98–100]"
    }, {
      "heading" : "2.1.3. Inorganic Nanomaterials",
      "text" : "Inorganic nanostructures, such as mesoporous silica NPs, QDs, noble metal NPs, lanthanide-based NPs, and semiconductor NPs, often possess unique optical, thermal, magnetic, and redox properties as well as suitability for straightforward surface functionalization, and therefore represent another major category of nanomaterials with important biomedical potential. Inorganic nanomaterials have been reported as emerging candidates i) as contrast agents for a wide range of bioimaging techniques such as dark-field, one-photon and two-photon, photoacoustic tomography, positron emission tomography, X-ray computed tomography (CT), and magnetic resonance (MR) imaging, ii) as therapeutic agents in chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), gene therapy, and radiotherapy, iii) as theranostics agents for simultaneous diagnosis and therapy of diseases, and iv) as vehicles to integrate diverse types of cytotoxic therapeutics into one single system.[101–105] For instance, QDs and upconversion NPs have\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (6 of 33)\ngreat potential as fluorescent probes in biological imaging or as nanocarriers in targeted delivery of anticancer drugs[106,107] (Figure 2c). Similarly, dye-doped magnetic mesoporous silica NPs could also be used simultaneously as a contrast agent in MR imaging and drug carrier with doxorubicin loaded in the pores, enabling imaging-guided anticancer therapy.[108] Surface plasmon resonance properties of gold, silver, and bismuth NPs have been widely explored for potential applications in biosensing, drug delivery, and phototherapy of diseases.[109–111] Inorganic nanomaterials also provide ready possibilities for additional surface functionalization, including: i) direct encapsulation by hydrophilic polymers, ii) ligand exchange with hydrophilic ligands, iii) formation of an interdigitated bilayer, and iv) doping with hetero-elements, finally improving their colloidal stability, water-solubility and flexibility, or further conferring additional biomedical functions in bioimaging and targeted drug delivery.[112–114] For inorganic nanomaterials, their disadvantages in biomedical application mainly involve difficulties in reproducible and massive production, aggregation, nonspecific toxicity, and undesirable biopersistence.[115]"
    }, {
      "heading" : "2.1.4. Carbon-Based Nanomaterials",
      "text" : "Due to their excellent biocompatibility, large specific surface area, and unique structural properties, carbon-based nanomaterials including fullerenes, metallofullerenes, nanodiamonds, single or multiwalled CNTs, graphene and their derivatives have drawn increasing expectations in medical applications ranging from drug delivery and bioimaging to tissue engineering and biosensor devices[116–119] (Figure 2d). The sp2 carbon network and the hydrophilic functional groups allow their functionalization either via noncovalent interaction with amphiphilic units and polymers, or via covalent linking with reactive intermediates of arynes, carbenes, nitrenes, and radicals, finally aiming to obtain extra nanomedical functions such as precise control over the drug release at the right place in drug delivery systems.[120–122] For example, Gd@C82(OH)22, a hydroxylated metallofullerene, was found to be essentially nontoxic to normal cells, while having the capability of imprisoning cancer cells through the inhibition of matrix metalloproteinases, resulting in high intrinsic inhibitory activity against cancer cells and high efficacy in the suppression of metastasis.[123–126] Biocompatible PEGylated CNTs and graphene oxide (GO) nanosheets showed very high loading capacity for hydrophobic chemotherapeutics through π-π stacking or hydrophobic interaction and have been regarded as intelligent drug delivery systems for these drugs.[127–129] Due to their strong NIR absorbance, such delivery systems could release their cargoes into the diseased regions upon NIR irradiation, enabling imaging-guided combined chemo-photothermal therapy. Alternatively, carbon-based nanomaterials attached with fluorescence probes or contrast agents have been exploited for bioimaging and biosensing.[130] Furthermore, carbon nanostructures as electron acceptors can efficiently quench the generation of single oxygen (1O2) generation by photosensitizers and then restore their photo sensitization with the aid of targeting events, leading to more efficient PDT as well as lower side effects.[131,132] Traditional implants combined with carbon-based nanomaterials have been reported to\nshow improved biocompatibility and mechanical properties, thus facilitating the development of multifunctional nanocomposites as scaffolds for soft (including cardiac, neural, and cartilage) and hard (including bone, dental, and craniofacial) tissue engineering applications.[28,29] Major challenges for the clinical application of carbon-based nanomaterials include their aggregation, conflicting results regarding their toxicity, as well as biopersistence.[40,133]"
    }, {
      "heading" : "2.2. Mechanisms of Nanotoxicity in Biological Systems",
      "text" : "While nanomaterial-induced toxicity against abnormal cells and tissues could be used to eliminate diseases, their undesirable toxicity to the normal tissues may cause adverse biological effects. To optimize both the performance and toxicity of nanomedicines, rational design of nanomaterials that aims to avoid their detrimental effects without losing the desired nanomedical functions is important. Understanding the possible bio-physicochemical interactions at the bio-nano interfaces and their consequences could provide critical information for the development of nano-QSAR model and then guidance of safe design of nanomaterials for medical applications, and open new possibility to improve their efficacy for disease treatment. In this section, we will summarize the currently known bio-nano interaction mechanisms that may shed a light on the safe design of nanomedicines for further clinical applications (Figure 3)."
    }, {
      "heading" : "2.2.1. Direct Physical Damage to Biological Membrane and DNA",
      "text" : "Nanostructures with rigid surface and sharp edges, in particular inorganic and carbon-based nanomaterials, are able to physically interact with the biological system and induce irreversible disruption of membrane structure,[134] activity,[135] and even the electron transport processes[136] in nanomaterial- and/ or concentration-dependent manners. Recent research has demonstrated that ZnO NPs could damage membrane of E. coli bacterial cells causing the formation of large holes.[137] Thin and rigid CNTs with needle-like structure could pierce the plasma and nuclear membranes of mesothelial cells, causing asbestoslike pathogenicity.[138] Likewise, the extremely sharp edges of GO could interact with both Gram positive Staphylococcus aureus bacteria and Gram-negative E. coli, directly damaging their membrane.[139] Molecular dynamics simulations have been employed to describe the interface interaction between graphene and biological membrane. The results revealed that graphene nanosheets were able to penetrate into membranes and extract large amount of phospholipids through the strong hydrophobic interactions between graphene and lipid molecules, compromising membrane integrity and stability, and even forming nanoscale holes.[140–142] Moreover, nanomaterials with at least one dimension less than 10 nm may directly penetrate the cell nucleus and damage the DNA structure, causing genotoxic effects including DNA strand breakage and chromosomal fragmentation.[143–145] Sargent et al. reported that singlewalled CNTs (SWCNTs) with the diameter of 1–4 nm could incorporate into the centrosome, resulting in mitotic spindle\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (7 of 33)\ndisruption, DNA fragmentation, and subsequent cellular aneuploidy.[146] CdTe QDs with the diameter of 3.4 nm could enter the nucleus via the nuclear pore complexes and subsequently interact with histone proteins.[147]"
    }, {
      "heading" : "2.2.2. Physical Interference",
      "text" : "Nanomaterials with similar size and shape to those of the key components within the cellular machinery may cause physical interference such as SiO2 and quantum dot-induced epigenetic effect[145,148] and the blockage of ion channels by CNTs.[149] Compared with the direct physical damages mentioned above, physical interference often occurs at much more subtle levels, tending to induce functional rather than structural damage. Both iron oxide NPs[150] and CNTs[151] could interact with actin myofilaments and cause abnormal cellular behavior including uncontrolled proliferation associated with cancer. Another study suggested that CNTs[152] and CdTe QDs[153] were able to sterically interfere with DNA, resulting in significant reorganization of the chromatin or heritable alterations in gene function. Remarkably, instead of direct DNA damage, physical interference mainly leads to altered gene expression via point mutation or translation inhibition.[145]"
    }, {
      "heading" : "2.2.3. Physical Interaction with Biomolecules and Organelles",
      "text" : "Once administered to the body, all types of nanomaterials readily interact with the biological constituents due to their high surface free energy. It is noteworthy that this bio-physicochemical interaction is dynamic in nature, and largely determined by the environment where nanomaterials are transported.[154,155] In biological fluids such as blood plasma, nanomaterials interact with numerous biomolecules, especially proteins and biological metabolites, forming biomoleculenanomaterial coronas, which further consist of the so-called hard and soft coronas depending on the binding strength and affinity of molecules present in plasma.[156] Of particular importance is that the biomolecules absorbed on the surface of nanomaterials often modify their biological properties, e.g., reducing their cytotoxicity[76] or affecting cellular uptake.[157] On the other hand, a rigid nanosurface may also mediate the native structure of biomolecules to unfold, hence alter their biological functions and enzyme activity of proteins, as observed in the activation of some inflammasome responses[158–160] or suppression of pancreatic cancer metastasis[126] mediated by nanomaterials. Nanomaterials also interact with cells and may trigger the activation of some physiological processes resulting in toxicity.[161,162] For example, nanomaterials like CNTs could interact with immune\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (8 of 33)\ncells such as platelets, neutrophils, and macrophages. This may lead to the generation of numerous cytokines like interleukins and tumor necrosis factor-α that are capable of further initiating a series of immune reactions and eventually fibrosis and bronchial granulomas.[163–166] Alternatively, NPs including SiO2, TiO2, and hydroxyapatite were capable of increasing cell contractility via massive disruption of the intracellular microtubule assembly without any apparent cytotoxicity, finally resulting in the promotion of strong substrate adhesions and limit of cell motility.[167,168] When endocytosed and then transported into endosomes via the fusion of lysosomes with late endosomes, nanomaterials may either be degraded under the acidic environment and/or by hydrolytic enzymes in the lysosome, releasing toxic components such as Ag+ from sliver NPs (AgNPs)[169] and Cd2+ from CdTe QDs,[170] or escape from lysosomes through the proton sponge effect, resulting in lysosomal dysfunctions.[171] The released nanomaterials sequentially generate inflammation and radical oxygen species (ROS), or interact with cytoplasmic biomolecules such as glutathione (GSH) and organelles including mitochondria and endoplasmic reticulum, leading to further dysfunction and even cell death.[172–174] Likewise, as discussed by previous reviews, nanomaterials may also induce autophagy dysfunction, resulting in either apoptosis or autophagic cell death.[175,176]"
    }, {
      "heading" : "2.2.4. Generation of ROS",
      "text" : "Overproduction of ROS by nanomaterials such as metal oxide NPs and carbon-based nanomaterials can cause oxidative stress, and subsequent mitochondrial damage, lipid peroxidation, and DNA damage.[177] The possible pathways for ROS generation by nanomaterials within cells have been discussed in detail by our previous review from a point of view of chemistry.[178] Briefly, ROS could be directly produced by: i) photocatalysis of metal and transition metal-contained NPs upon light (mainly in the ultraviolet region) irradiation, ii) chemical reactions of metal oxide NPs with biological redox species such as cytochrome c and GSH, and iii) catalytic conversion of nontoxic intracellular compounds into ROS by nanomaterials consisting of multivalent metal element, e.g., iron oxide, Cu2O, and CeO2 NPs. In addition, ROS may be indirectly generated by nanomaterials mainly through i) disruption of the electron-transport chain in mitochondria, ii) interaction with redox active enzymes such as nicotinamide adenine dinucleotide phosphate oxidase, iii) activation of intracellular ROS-related signaling pathways like epidermal growth factor receptor signaling, and iv) activation of immune cells like macrophages and neutrophils.[179] Typically, many studies have exhibited that iron oxide NPs were capable of catalytically converting intracellular hydrogen peroxide (H2O2) into more toxic hydroxyl radical (HO•) via the Fenton, Fenton-like, or Haber–Weiss cycle reactions, causing oxidative damage or even cell death.[180] Besides, our previous study demonstrated that GO nanosheets could generate ROS via catalytically conversion of H2O2 to HO• and NDUFB9-mediated biological pathway, resulting in oxidative stress-induced cytotoxicity.[181,182] More importantly, it was found that both direct and indirect ROS production by GO nanosheets was heavily related to their oxidation degree.\nIt is worthwhile to note that the specific toxic effects induced by nanomaterials in a selective manner can be applied for advanced therapeutics during use in practice, instead of side effects. For example, Setyawati et al. found that nanodiamonds and AuNPs could induce the loss in endothelial cell–endothelial cell connections of the vascular barrier and the quasi-stable cytoskeletal remodeling via increasing intracellular ROS and Ca2+.[183–185] This increase in leakiness is capable of enhancing the penetration of doxorubicin and then leading to the improvement of the cancer killing effect. Moreover, further studies find that the physicochemical properties of nanomaterials such as size, charge, and even density changes have significant impact on the nanomediated endothelial leakiness (NanoEL).[186–188] These findings show that surface functionalization of nanomedicines is an alternative to help the cancer nanomedicine traverse across the vascular barrier. Alternatively, cytotoxic autophagy induced by GO nanosheets after intratumoral injection could lead to the inhibition of cancer growth through TLR signaling.[189] During this treatment, the autophagy machinery like Beclin-1 was up-regulated via the activation of TLR-4/9, thus showing significantly anti-cancer both in vitro and in vivo."
    }, {
      "heading" : "3. Safe-by-Design Strategies for Nanomedicine",
      "text" : "Efforts to minimize the toxicities of biomedical nanomaterials could be devoted to diverse stages of their life-cycles. The use of personal protective equipment and remote control techniques during their manufacturing or application is necessary and helpful, yet such strategies are not able to reduce or eliminate the intrinsic toxicity of nanomaterials. Therefore, attempts to mitigate the potential risk of nanomaterials during their design are more attractive and greatly facilitate the clinical application of nanomedicines. By particularly addressing the known nanotoxicological mechanisms discussed above, several safe-by-design approaches and principles have been proposed to develop safer nanomedical products while retaining their desired functions."
    }, {
      "heading" : "3.1. Current Approaches to Safe-by-Design Nanomedicines",
      "text" : ""
    }, {
      "heading" : "3.1.1. Coating and Encapsulation",
      "text" : "Enclosing toxic nanostructures, in particular inorganic NPs, within amphipathic lipids, polymers, silica, ZnS, or other more biocompatible materials, is one of the most widely used method to prevent the release of toxic components from the core and thus to reduce their potential adverse effects[190–192] (Figure 4a). Typically, nanomaterials are dispersed in an organic solvent and uniformly mixed with coating agents, allowing which to form a shell layer on the nanomaterial surface through the evaporation of solvent or chemical and biological reactions. Compared to bare core nanostructures, such core-shell nanomaterials are often more water-soluble and colloidally stable, and have weaker nonspecific interactions with biomolecules.[193,194] For example, hydrophobic QDs (such as CdSe/CdS/ZnS and CdTe)[195,196] and iron oxide NPs[197] have been successfully encapsulated within silica either to improve their stability and biocompatibility, or to introduce extra functions.\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (9 of 33)\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (10 of 33)"
    }, {
      "heading" : "3.1.2. Loading",
      "text" : "“Loading” refers to an approach by which organic molecules, polymers, or biomolecules are noncovalently attached to the surface of nanomaterials via van der Waals forces, hydrophobic and electrostatic interaction, π–π stacking, or hydrogen bonding[198–200] (Figure 4b). Unlike the concrete and strongly attached shells described in the previous section, such “loaded” layers are relatively loose and suitable for further loading of drugs and various bioactive agents. Moreover, this approach may introduce numerous hydrophilic moieties such as NH2, COOH, and SH onto the outer surface of nanomaterials, to which multiple targeting ligands can be covalently attached, enhancing its targeting ability to diseased sites.\nThere are two major types of “loading” that have been reported in previous literature. In one of them (“loading-to” approach), bare nanostructures serve as the vehicle to load functional molecules, nanostructures, and polymers onto their surface. Due to its simplicity and high efficiency, such method has been extensively employed for the design of nanomedicines with enhanced and combined nanomedical functions. For example, a wide range of nanomaterials such as QDs, Fe3O4 NPs, CNTs, and graphene or its derivatives have been loaded with DSPE-PEG to improve their dispersibility and biocompatibility for drug delivery and bioimaging.[201–203] This method is also particularly suitable for the functionalization of inorganic and carbon-based nanomaterials.\nAnother type of “loading” technique (“loading-from” approach) involves the process in which nanomaterials are attached on the surface of another structure or embedded into a matrix to form nanocomposites. Such an approach has been widely employed to fabricate multifunctional polymer nanocomposites composed by polymer matrices and small amount of nanoscale additives, endowing them with enhanced electrical, mechanical, or optical properties that are useful for their applications such as tissue repair and regeneration.[204,205]"
    }, {
      "heading" : "3.1.3. Grafting",
      "text" : "“Grafting” is a technique by which functional moieties such as probe molecules and targeting ligands are covalently attached to nanomaterials[206–208] (Figure 4c). This method requires functional groups like NH2 and COOH on the nanosurface to provide reactive sites. Similar to the case of “loading” technique, there are two major types of “grafting” to which we here refer as “grafting-to” and “grafting-from.”\n“Grafting-to” method involves the attachment of reactive species with surface-functionalized nanostructures through chemical reactions like the N-(3-Dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride chemistry.[209] The drawbacks of this approach include that: i) the density of the grafted species is relatively low due to steric repulsions, and ii) the reaction becomes less efficient with species of higher molecular weight. Nevertheless, this method is easy to perform and the covalent binding between grafted species and nanosurface makes such attachment robust enough to resist chemical efforts.\n“Grafting-from” method refers to embed nanomaterials into a matrix via covalent linkages, most commonly using\ninitiator-functionalized nanostructures to trigger the formation of polymeric matrix via polymerization. This approach can produce composites with high grafting densities of nanostructures and has been widely used to fabricate tissue engineering materials."
    }, {
      "heading" : "3.1.4. Doping",
      "text" : "Doping of nanomaterials signifies the introduction of a small percentage of foreign atoms into an otherwise pure material (e.g., inorganic and carbon-based nanomaterials) to modulate their electrical, optical, or magnetic properties[210,211] (Figure 4d). Importantly, doping nanocrystals with impurities could alter their energy-band properties, therefore tuning the electron transfer kinetics between the nanocrystals and biological redox couples.[212] Besides, the formation of heterostructures on nanocrystal surfaces can lead to a local change in the energy offset of band structure near the surface (e.g., band bending effect), promoting charge separation in the heterostructure.[213] Both of these events may influence the energy level alignment in the doped nanocrystals and therefore affect its ROS generation and oxidative stress.[214–216]"
    }, {
      "heading" : "3.2. Principles for Safer Design of Nanomedicines",
      "text" : "Now, the material research community has caught on “safeby-design” strategies to create sophisticated nanostructures because the common nanomaterials have been around for decades and a large number of information has been achieved during this process. However, cutting-edge nanomedicine has not reached the same level of maturity to adopt the safe-bydesign principles of the common nanomaterials. Moreover, most of studies of the nanomedicine research community mainly focus on getting the nanomedicines to work, but not on the safety aspects. Another major challenge in the promotion of safe-by-design strategies is that both the nanomaterials with potential in medical application and the methods and techniques available to incorporate them into nanomedicines are enormously diverse. It is therefore necessary to establish useful general guidelines in how to mitigate the health risks, and cover a wide range of nanomaterials with clinical implications, so as to minimize the effort need for the further optimization of each individual case. In this section we have proposed seven principles that have been extensively tested in previous research and could serve as the initial framework for scientists and technicians to address the nanomaterial-related risks by optimizing their design and to develop nanomedicines with minimized intrinsic toxicity for clinical application."
    }, {
      "heading" : "3.2.1. Optimizing the Size and Structure of Nanomaterials",
      "text" : "Size (including dimensional parameters such as length, width, diameter, etc.) and structure (including shape, porosity, crystal structure, chemical composition, and aggregation, etc.) of nanomaterials have long been recognized as the major determinants of their performance and toxicity. Therefore, it is important to\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (11 of 33)\ntune these properties with precision to improve the pharmacokinetics and biodistribution of nanomaterials while keeping their desired functions intact (Figure 5a).\nWhen administered in vivo, nanomaterials with smaller size are rapidly secreted from the body through renal filtration into the urine; while larger nanostructures are mainly captured by the organs of reticuloendothelial system including lung, liver, and spleen.[217,218] Both routes of clearance limit the circulation half-life of nanomedicines, consequently decreasing their chance of reaching the target sites and increasing potential adverse effects. Identifying the optimal size of nanomaterials for in vivo application is therefore essential. Many studies showed that, for anticancer nanomaterials, the suitable size for systemic administration ranges between 2 and 200 nm, which endows the nanomaterials with an acceptable circulation halflife and allows them to accumulate in the tumors through the EPR effect.[219,220] Tang et al. reported that a silica-drug nanoconjugate with a diameter of ≈50 nm exhibited higher tumor tissue retention over time compared to the counterparts of 20 nm or 200 nm diameter, which was mainly attributed to deeper tumor tissue penetration, more efficient cancer cell internalization, and slower tumor clearance[221] (Figure 5b–h). The results also indicated that the 50 nm nanoconjugate showed the highest therapeutic efficacy against both primary and metastatic tumors in vivo. Another work found that AuNPs with smaller diameter, e.g., 15 nm and 30 nm, showed higher tumor uptake than larger nanoparticles (45, 60, and 100 nm) in an orthotopic MDA-MB435 tumor model.[222] Moreover, tumor uptake of 15 and 30 nm AuNPs steadily increased from 0.39 ± 0.04% to 0.99 ± 0.18% ID and 0.28 ± 0.03% to 0.90 ± 0.18% ID, respectively, as tumor volumes increased from ≈0.5 cm3 to ≈2.2 cm3. Further study showed that AuNPs larger than 100 nm in diameter hardly penetrated into MDA-MB-435 tumors.[223] Based on their sizedependent biological effects, AuNPs with the diameter in the range of 2–50 nm may be more suitable for the development of nanomedicines with higher tumor targeting efficacy and fewer side effects. As for nanorods, their aspect ratios remarkably influenced their antitumor activity. Wang et al. found that gold-coated mesoporous silica nanorods with approximate dimensions of 207 × 105 nm showed more efficient cellular uptake and deeper penetration into tumor tissues than those of nanorods with approximate dimensions of 125 × 55 nm and 207 × 155 nm.[224] Since nanorods with a moderate aspect ratio have superior accumulation and distribution profiles within tumors, they have also induced the most effective ablation of malignant melanomas under mild laser irradiation. Structure of nanomaterials also strongly affects their fundamental properties.[225] The optical absorption efficiency of gold nanorods was reported to be ≈20-fold higher compared with gold nanospheres with the same volume;[226] and the scattering coefficient per micrometer of gold nanorods was also higher than those of gold nanoshells and nanospheres.[227] These make gold nanorods a particularly promising candidate for cancer treatment in terms of imaging-guided PTT. Ali et al. demonstrated that gold nanorods with an average length of ≈25 nm and a diameter of ≈5.5 nm were highly effective and safe for\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (12 of 33)\nlocal plasmonic PTT of cancer in the mouse models.[228] Besides, Wang et al. reported that gold nanohexapods as PTT agents showed higher cellular uptake and antitumor efficacy but lower cytotoxicity than gold nanorods and nanocages.[229] These above studies clearly demonstrate that the optimization of the size and structure of nanomaterial-based agents is critical for the development of safe nanomedicines."
    }, {
      "heading" : "3.2.2. Regulating Nanomaterial-Related Perturbation of Cellular Redox Equilibrium",
      "text" : "As mentioned above, many nanomaterials (in particular inorganic and carbon-based nanomaterials) are capable of perturbing the balance between the oxidized and reduced species located within the cell by depleting electrons from the biological redox species and/or catalyzing ROS-related reactions at the bionano interfaces.[230,231] The overall result is usually an increased production of ROS, leading to inflammatory responses and even necrosis. In order to regulate the ROS generation of nanomaterials and avoid unwanted perturbation of the cellular redox equilibrium, their energy band structures could be tailored by doping, metal loading or heterojunction coupling (Figure 6a).\nIt is highly favorable to ensure that the conduction band energy levels of involved nanomaterials are more negative than the standard redox potentials of the biological redox couples (from −4.12 to −4.84 eV) active in the relevant media, resulting in the inhibition of the electron transfer from biological redox species to nanomaterials and minimization of the generation of ROS. Zhang et al. have applied this principle to help the screening of safe nanomaterials for biological applications.[232] Metal oxide NPs with more negative conduction band energy level such as HfO2, Gd2O3, Y2O3, and SiO2 did not significantly produce ROS and showed lower toxicity. In fact, HfO2 NPs have been successfully tested as promising radiosensitizers to enhance radiotherapy,[233] Gd2O3 NPs as contrast agents for CT and MR imaging,[234] Y2O3 NPs as upconversion fluorescence probes for bioimaging and biosensing,[235,236] and SiO2 NPs as nanocarriers for drug delivery.[237] In contrast, due to the overlap of their conduction band energy levels with the biological redox potential (BRP) range, Co3O4 NPs were reported to oxidize cytochrome c inducing ROS production and inflammation. In addition, when Co3O4 NPs were doped with PdO to form heterojunction, band bending effect further facilitated the charge separation between PdO and Co3O4 to generate extra HO• at the Bio-Nano interface, making Co3O4 NPs even more toxic[238] (Figure 6b–i). Significantly, accompanying the gradual increase of the PdO content (from 0 to 8.9%), the conduction band levels of product nanoparticles showed increased energy overlap with the BRP, overwhelming the cellular redox homeostasis in BEAS-2B and RAW 264.7 cells and causing increased oxidative stress with a tiered cellular response. Cheng et al. reported the introduction of deep level defects into Bi2S3 nanorods via the formation of Bi2S3-Au heterostructures could greatly improve their photothermal performance, causing more severe cell death and greater tumor growth inhibition under an 808 nm laser irradiation.[239]\nHowever, in the case of using nanomaterials for antibacterial applications, it is desired that nanomaterials have an energy band gap active to ultraviolet and even visible lights and that\ntheir conduction band energy levels are more positive than the BRP in the bacteria. Li et al. demonstrated that TiO2, ZnO, Al2O3, SiO2, Fe2O3, and CeO2 NPs were capable to generate electron-hole pairs when excited by ultraviolet light.[240] The photoexcited electrons then reacted with aqueous electron acceptors such as molecular oxygen (O2) to form O2•−; in parallel the photoexcited holes interacted with aqueous electron donor like water to yield HO•. These radical species consequently inhibited the proliferation of E. coli. To further enhance the antibacterial activity of nanomaterials, doping with metal and nonmetal element was applied to tune their Fermi energy levels and band gap. Remarkably, doping TiO2 NPs with Fe resulted in a shift of their photoactivation spectrum from ultraviolet to visible region and enhanced their photoactivity and ROS production under light irradiation.[241] Likewise, doping ZnO NPs with Al, Cu, and Mg could reduce their band gap, rendering them more effective in transforming the input light energy into ROS generation.[242–244] Besides, doping of metal elements into nanomaterials can alter their fluorescence properties, facilitating their application for bioimaging and biosensing. One example is that doping suitable matrices such as Y2O3 and NaYF4 with rare earth elements (e.g., Yb3+, Er3+, and Tm3+) could endow them with the capability to convert low-energy light (usually NIR light) to higher-energy light (ultraviolet-visible light), making these upconversion NPs promising probes for bioimaging with attractive advantages such as deep penetration depth and no interference from auto-fluorescence of biological tissues.[22,245]"
    }, {
      "heading" : "3.2.3. Passivating Defect Sites of Nanomaterials",
      "text" : "There are many evidences that have demonstrated that the surface of a nanostructure is often rich in different types of defects, including steps, kinks, edges, and corners[246] (Figure 7a). Atoms located at these defect sites possess unsaturated dangling bonds, resulting in the local change of both surface electronic structure and allowed energies, endowing such sites with enhanced chemical reactivity. This makes surface defects of nanomaterials a favored medium for chemical, biological, and toxicological processes at the bio-nano interface.[8] Muller et al. reported that defects on the surface of multiwall carbon nanotubes (MWCNTs) tended to generate ROS, leading to increased toxicity under in vivo conditions.[247] In this sense, passivating these surface defects during material fabrication may be helpful for the inhibition of such toxic surface reactions without cancelling the desired properties of nanomaterials (Figure 7a).\nGeorge et al. reported that surface coating with cysteine could reduce or even eliminate the high cytotoxicity and membranolytic injury in vitro caused by Ag nanoplates, nanospheres, and nanowires which could be attributed to the crystalline defects on their surface including point defects and stacking faults.[248] Investigations using a zebrafish model confirmed that the mortality rate in zebrafish was the highest for Ag nanoplates. Alternatively, Cai et al. reported that passivating the surface of MOx NPs (TiO2, CoO, CuO, Ni2O3, and Co3O4) by ethylenediamine tetra(methyle-nephosphonic acid) (EDTMP) effectively reduced their surface activity, leading to an 85–99% decrease of oxidative potential[249] (Figure 7b,c). The EDTMP-coated MOx NPs induced negligible ROS generation and cell death in both\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (13 of 33)\nTHP-1 and BEAS-2B cells. The protective effect of EDTMP coating was further validated in mice whose lungs were exposed to MOx through oropharyngeal aspiration. It was found that, after 40 h exposure, EDTMP-coated MOx treated lungs showed significantly lower levels of MCP-1, IL-6, LIX, neutrophil counts, and lactate dehydrogenase release in bronchoalveolar\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (14 of 33)\nlavage fluid, compared to uncoated NPs. The haematoxylin and eosin staining results of lung tissue demonstrated that EDTMP coating remarkably reduced the pulmonary inflammation. Coating ZnO[192] and iron oxide[250] NPs with silica shells also shielded their surface reactive sites, improving their stability and biocompatibility, without significantly diminishing their functionality. In another work, Wang et al. reported that when AuNPs were coated with chiral penicillamine molecules, the chirality of the coating ligands determined the orientation and conformation of surface-adsorbed transferrin.[251] Specifically, transferrin adsorbed on AuNPs coated with L and racemic penicillamine showed weaker binding to transferrin receptor than transferrin adsorbed on of D-penicillamine coated AuNPs, which resulted in the decrease of their tumor targeting ability as increasing their off-target side effects. In addition to passivating the nanosurface surface, coating nanomaterials with agents such as organic molecules, biocompatible polymers, or biomacromolecules also modulate their nanotoxicity via inhibiting the electron transfer between nanomaterials and the intercellular components like GSH and cytochrome c.[252,253]\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (15 of 33)"
    }, {
      "heading" : "3.2.4. Reducing Interaction between Nanomaterials and Biomolecules",
      "text" : "Due to their high surface free energy, nanomaterials always tend to interact with the biological molecules such as proteins, DNA, lipids and even metabolites, once entering the body. These bio-physicochemical interactions at the bionano interface may induce structural and functional alterations to the biomolecules and cause unpredictable adverse health effects,[254,255] as well as heavily affecting the blood circulation time of nanomedicines.[256] For example, ZnO NPs\nwith the diameter of ≈20 nm could selectively interact with β-galactosidase to inhibit their catalytic activity.[257] We hence suggest that nanomaterials should be engineered to avoid nonspecific interaction with biomolecules (Figure 8a).\nBoth “loading” and “grafting” methods discussed above are feasible routes to modify nanomaterials with a “stealth corona,” i.e., a hydrophilic shell that can shield them from protein absorption, liver uptake, and/or phagocytic uptake, so as to reduce nonspecific bio-nano interaction and prolong nanomaterial blood circulation.[258,259] So far, natural and semisynthetic polysaccharides, synthetic polymers and\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (16 of 33)\nsome proteins have been developed for stealth coatings.[260] Benefiting from its neutral electricity, flexibility, and hydrophilic properties, polyethylene glycol (PEG) with linear and branched structures is the most widely used “stealth” polymer for nanosurface modification.[261–263] For instance, PEGylation of liposomes,[264] polypeptides,[265] and polymeric NPs[266] has been reported to endow these nanomaterials with enhanced stealth properties and increase their circulation time. PEG coating is also able to effectively reduce the direct contact of nanomaterials with biomolecules. Notably, the molecular weight, chain length, conformation, and surface density of attached PEG polymer heavily influence the protein resistance and circulation time of PEGylated nanomaterials in blood. For example, Miteva et al. demonstrated that increasing the molecular weight of PEG from 2 to 20 kDa could prolong the blood circulation half-life of endosomolytic mixed micelles from 4.6 to 17.7 min, meanwhile leading to a fourfold decrease in lung accumulation.[267] Walkey et al. reported that the amount of protein adsorption on gold NPs decreased with the increase in the density of the PEG coating[268] (Figure 8b–e). The impact of PEGylation on in vivo behaviors of nanomaterials has been summarized and discussed in the recent reviews.[269,270] Based on such knowledge, nanomedicines resistant to protein adsorption could be engineered by optimizing the structure and the surface density of PEG coating. In addition, PEGbased copolymers including polyglutamic acid, poloxamers, and polysorbates were also applied as stealth coatings to make nanomaterials “invisible” to proteins in the physiological fluids.[271–274]\nDespite of being able to enhance protein resistance and increase circulation time for nanomaterials, PEGylation does not completely inhibit nonspecific protein adsorption.[268] Moreover, it has been reported that PEG-based coatings may introduce other problems such as nondegradation and hypersensitivity.[275,276] Possible alternatives to PEG include synthetic polymers such as polyoxazolin,[277] polyvinyl pyrrolidone,[278] polyacrylamide,[279] zwitterions,[280] and their block copolymers,[281] natural polysaccharides such as dextran,[282] chitosan,[283] hyaluronic acid,[284] and heparin,[285] biomolecules such as polyaminoacids,[286] albumin,[287] and biomembrane,[288] as well as siliconate treatment.[289] Biodegradable polymers including chitosan, poly(phosphoester) and polyglutamic acid have achieved great attention for medical applications since they could be enzymatically hydrolyzed and degraded into nontoxic small molecules and do not accumulate in the body.[290] For example, hydroxyethyl starch (HES), a starch derivative that can be decomposed in vivo by amylases, has been applied to fabricate biodegradable nanocarriers with low unspecific interactions with biological components and prolonged circulation time in blood.[291,292] Such nanocarriers may also be further functionalized with targeting agents to simultaneously inhibit nonspecific bio-nano interactions and enable specific targeting. A study reported by Kang et al. showed that HES nanocarriers functionalized with mannose still kept their targeting ability after incubation with plasma, and could be specifically taken up by dendritic cells[293] (Figure 8f–h). These results are helpful for the design of nanomedicines with the goal of improving their therapeutic efficacy and reducing their side effects."
    }, {
      "heading" : "3.2.5. Preventing the Leakage of Toxic Components",
      "text" : "During the application of nanomedicines, it is possible that hazardous species (e.g., polymer degradation products and ions) are released by the nanomaterials (e.g., Ag+ from AgNPs) or individual nanostructures dissociate from the nanocomposites, both of which may potentially causes of adverse effects.[33,294] By proposing this principle we would like to underline the importance to prevent such release or dissociation of toxic species from nanomedicines during medical use (Figure 9a).\nStability of nanocomposites-based nanomedicines could be improved by enhancing the interaction (e.g., van der Waals force, coordination, electrostatic interaction, as well as hydrogen and covalent bonding) between components using ligands or compatibilizers to prevent early detachment of nanomaterial units.[295–297] For example, using “loading” method, we have designed the upconversion luminescent graphene-based nanocomposite film with nacre-like structures for optical pH sensing.[298,299] By optimizing the content of branch polyethylenine-functionalized upconversion (PEI-NaYF4:Yb,Er) nanocrystals in the film, we were able to strongly enhance its interlayer adhesion by taking advantage of the strong electrostatic interaction between negative charged graphene nanosheets and positive charged nanocrystals, as well as to improve its mechanical properties. After repetitive cycling between pH 8.00 and pH 6.00, few PEI-NaYF4:Yb,Er nanocrystals released from the nanocomposite, and there was almost no change in its luminescence intensity. Another study reported the fabrication of multifunctional composite films composed of poly(vinyl alcohol) and reduced GO using poly(vinyl alcohol) as the “mortar” to adhere adjacent GO nanosheets and endowed the product film with strong stability.[300]\nAs for the dissolution issue of nanomaterials, in particular those of metallic composition or containing residual metallic impurities, several engineering strategies such as the coating of polymers[301] and thiols[302] have been tested to decrease their release of toxic species. Tejamaya et al. demonstrated that polyvinyl pyrrolidone modified AgNPs had superior stability compared to both citrate- and polyethylene glycol-functionalized counterparts, preventing their shape change and dissolution in ecotoxicology media.[200] Long et al. reported that coating 10 nm AgNPs with mercaptohexanoic acid could efficiently prevent the release of Ag+ ions, inhibiting their toxicity against microorganisms.[303] Notably, different coatings induce different surface properties which may result in coating-specific bio-nano interactions as well as toxicity.[304] The correlation between the cytotoxicity of NPs and their surface coating has been discussed by Suresh et al., aiming to instruct the rational design of nanomaterials.[305] Silica coating provides an attractive solution for the complete enclosure of nanomaterials within a thin nanosilica layer.[112] Sotiriou et al. proposed a safe-by-design approach to encapsulate ZnO nanorods in an amorphous SiO2 shell through gas-phase synthesis[306] (Figure 9b–e). Using the Nano-Cometchip assay, they found that the as-prepared product exhibited minimal DNA damage while retaining the optoelectronic properties of the ZnO core. Doping with metallic elements is another strategy to reduce the dissolution of nanomaterials with the advantage of better preserving their inherent physicochemical properties compared to other existing approaches. Xia et al. demonstrated that doping of ZnO NPs\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (17 of 33)\nwith Fe could significantly reduce the Zn ion dissolution rate in physiological solutions, which greatly improved the toxicological profile of ZnO NPs in animals[307,308] (Figure 9g–j). Another study using Al-doping ZnO NPs has reported similar observations.[309] Likewise, doping CuO NPs with Fe also reduced their toxicity.[211] Fe-doping decreased the planar bond length and increased the apical bond length of CuO, inducing structural distortion (Jahn-Teller distortion). The formation of CuFe2O4 on the NP surface inhibited the dissolution reaction of CuO and thus reduces their toxicity after exposure to zebrafish embryos."
    }, {
      "heading" : "3.2.6. Controlling the Biopersistence of Nanomaterials",
      "text" : "Biopersistence refers to the long-term presence of nanomaterials in a living organism without any alternation. Unlike small\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (18 of 33)\nmolecule drugs, which are usually metabolized by organs such as liver after administration and excreted over time, many nanomaterials accumulate in certain tissues for months and even years once entered the body, causing probable longer-term toxicity.[310–312] Engineering such nanomaterials to reduce their biopersistence is therefore essential for their medical application, and multiple functionalization strategies have been developed to improve their degradation and clearance while avoiding inappropriately short half-life and the release of toxic components (Figure 10a). Based on their compositions, nanomaterials can be primarily classified into “soft” nanostructures and “hard” nanostructures. The category of “soft” nanostructures mainly include those composed of organic molecules, polymers and biomolecules, e.g.,\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (19 of 33)\nliposomes, emulsions, micelles, polymeric nanomaterials, and protein NPs. These materials usually exhibit acceptable biocompatibility and can be degraded under proper physiological conditions or by enzymes.[313,314] “Hard” nanostructures, such as metal (e.g., Au, Ag, etc.), metal oxide (e.g., ZnO, TiO2, etc.), and carbon-based nanomaterials (e.g., CNTs, graphene, fullerene, etc.) are typically more persistent in vivo, displaying prolonged retention time in the body.[315] Therefore, solutions to improve the biodegradation of inorganic and carbon-based nanomaterials are of particular interest and will be discussed below.\nModifying nanomaterials with specific functional groups is a widely used approach to tune their biopersistence. Seré et al. demonstrated that mesoporous silica NPs functionalized with triethanolamine (TEA) degraded much faster than both carboxylated and nonfunctionalized NPs, with their degradation rate showing a TEA dose-dependent manner[316] (Figure 10b–d). Moreover, it was found that synthesis parameters such as temperature and base concentration influence the degradation behavior of mesoporous silica NPs. Other studies have demonstrated that some carbon-based nanomaterials are susceptible to enzymatic degradation associated with the innate immune system.[133,317,318] Allen et al. first reported that carboxylated SWCNTs could be slowly degraded by oxidation via a highly reactive intermediate resulted from the reaction of horseradish peroxidase (HRP) with H2O2[319] (Figure 11a–f). Later, other carbon-based nanomaterials including GO and MWCNTs have also been demonstrated as degradable by HRP and H2O2,,[320,321] and SWCNTs have been reported to be degraded by other mammalian peroxidases with the catalytic heme active site in the presence of H2O2 or halide ions.[322,323] As shown in Figure 11g–k, GO could be oxidized to form holes on its basal plane after 5 and 10 d of HRP/H2O2 treatment. Furthermore, increased density of functional groups and defectiveness of carbon nanomaterials may allow closer proximity with the active site of enzymes, and therefore faster degradation.[324] Sureshbabu et al. found that CNTs functionalized with coumarin and catechol moieties showed much higher biodegradation rate compared to oxidized counterparts, which was mainly attributed to the ability of these groups to enhance the interaction between CNTs and activating HRP.[325] These suggest that the biodegradation of carbon-based nanomaterials could be modulated via introducing functional moieties, facilitating on-demand degradation of nanomaterials that are required in the area of regenerative medicine."
    }, {
      "heading" : "3.2.7. Introducing Stimuli Responsiveness",
      "text" : "The so-called smart nanomedicines, designed to achieve maximum theranostics specificity and controllability by only revealing their cytotoxicity in response to specific stimuli such as pH, redox potential, and temperature, have long been regarded as one of the most attractive novelties enabled by nanotechnology in the field of medicine.[129,326–329] As demonstrated by pre-clinical animal studies, such stimuli-responsive systems are more effective and less toxic compared to traditional nanoformulations that release their cargoes passively. In this section, we would discuss the various strategies of engineering responsive nanomaterials to produce smart nanomedicines that\nare active to diseases only after reaching their target destination (Figure 12a).\nMany types of stimuli-responsive nanomaterials have already been designed for potential medical application, examples of which include magnetic-responsive liposomal systems,[330] GSH-responsive polymeric systems,[331] light-responsive mesoporous silica systems,[332] pH-responsive graphene system,[333,334] and electric field-responsive GO nanocomposite film.[335] In contrast to the traditional therapeutics that are always “on” during the therapeutic process, these systems are only “turned on” in response to a specific signal, and some of them can be activated and deactivated reversibly turning the treatments “off” when the signal stops/disappears.[105,336] For example, our group has developed a selective PDT agent using GO as vehicle to which were integrated targeting aptamers and the photosensitizer Ce6[337] (Figure 12b,c). In this system, 1O2 generation could be efficiently quenched by close proximity of Ce6-labeled aptamers to GO. However, in the presence of the designed target ATP, the binding to ATP of aptamers disturbed their interaction with GO, causing them to fall off the GO surface, and leading to an increase in 1O2 generation and effective photodynamic killing of cancer cells with reduced side effects. Alternatively, Cho et al. developed a PDT system where Ce6 was conjugated with GO nanosheets via the redoxresponsive cleavable disulfide linker (GO-SS-Ce6).[338] In the presence of reductive agents like GSH, the disulfide bonds in GO-SS-Ce6 were cleaved to recover the photoactivity of Ce6 and restore 1O2 generation under light irradiation. Another study developed a tri-stimuli-responsive biodegradable theranostic system by using copper sulfide doped periodic mesoporous organosilica NPs (CuS@PMOs). The as-made CuS@PMOs have been employed as nanocarriers to load and then release doxorubicin in response to the combination of intracellular GSH, acidic tumor microenvironment, and external laser irradiation. Both in vitro and in vivo results demonstrated their significant enhanced chemotherapeutic efficacy without recurrence. Li et al. constructed a smart nanorobot based on DNA origami with the blood coagulation protease thrombin located in its inner cavity and aptamers targeting nucleolin, a tumor blood vessel specific protein, conjugated outside[339] (Figure 13). When recognizing the nucleolin molecules on the endothelium of tumor vasculature, the DNA nanorobot could be mechanically opened to expose the concealed thrombin and cause tumor-specific intravascular thrombosis to inhibit tumor growth. Stimuli-responsive nanomedicines have been attracting gradual attention during the past decades, and more detailed discussions on their design or application may be found in several recent reviews.[340–343]"
    }, {
      "heading" : "4. Conclusion and Future Perspectives",
      "text" : "Numerous efforts have been devoted so far to uncover the underlying mechanisms of nanomaterial toxicity and use the resulted knowledge as guidance to the design of safe nanomedicines. With the help of many well-established fabrication techniques, diverse types of nanomaterials, such as liposomes, polymers, mesoporous silica, CNTs, and graphene, have been explored to construct effective yet safe nanosystems\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (20 of 33)\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (21 of 33)\nfor applications including drug delivery, bioimaging, tissue engineering and biosensing. In order to promote the rational design of nanomedicines and minimize their intrinsic heath risk, it is of importance to understand the relationship between the design and biological effects of nanomaterials, and then extract principles useful for developing safer nanosystems for medical use. Fundamental physicochemical properties of nanomaterials such as size, structure, energy band structure,\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (22 of 33)\nand surface defects directly determine their behaviors in biological environment, and should be carefully controlled during the engineering and fabrication of medical nanomaterials. Interactions with components of biological system, such as proteins, cells and other biomolecules at the bio-nano interface, could be modulated by engineering the nanomaterials using techniques like surface coating, functionalizing, doping, or combination of multiple types of nanostructures to obtain favorable in vivo biodistribution, biodegradation, and clearance profiles. The balance between efficacy and toxicity could be further optimized by introducing stimuli-responsive features into nanomedicine design to direct their activity only against diseased cells and tissues, therefore significantly minimizing the possible adverse effects.\nIn recent years, various types of nanomedicines with the advantages of enhanced solubility, improved pharmacokinetics and efficacy, and minimized toxicity, compared with the conventional molecular drugs, have already been created by using the above strategies and principles for a wide range of applications including imaging, in vitro diagnostics, drug delivery, in vivo therapeutics, and active implants.[186] To data, more than 300 products have been under clinical trials, and even more are being investigated in the laboratory.[344–347] Encouragingly,\nabout 60 products have been approved by the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of various diseases[347–350] (Table 1). In general, liposomes and polymeric nanomaterials receive considerable interest for drug delivery due to their excellent biodegradability. For example, encapsulation of doxorubicin in PEGylated nanoliposomes (Doxil) could changes its pharmacokinetics and biodistribution, and improve the drug concentration in malignant effusion due to the EPR effect (≈4–16-fold higher than that of free doxorubicin)[13] (Figure 14a,b). Such effects can lead to prolong survival for patients treated with Doxil, as well as reduce side effects[351] (Figure 14c). Another example is that cationic liposomes and polymeric nanomaterials which are capable of rupturing lysosomes via the proton sponge effect to induce toxicity.[34] To improve their biocompatibility, “grafting” approach has been applied to reduce the excessive cationic charge density and prevent nonspecific interactions with biomolecules through covalent functionalization of polymer chains hydrophilic moieties such as PEG.[352]\nUnlike liposomes and polymeric nanomaterials, inorganic and carbon-based nanomaterials attract great attention for biosensing, diagnostics and therapeutics mainly owing to their unique electronic, optical, and redox properties. However,\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (25 of 33)\nAdv. Mater. 2019, 1805391\ninorganic and carbon-based nanomaterials may generate toxicity via i) direct or indirect generation of ROS, ii) dissolution of toxic species, and iii) organelle dysfunctions induced by their intracellular accumulation. Therefore, one could optimize the physicochemical properties of inorganic and carbonbased nanomaterials according to the safe-by-design strategies including coating, loading, and grafting techniques to passivate their defect sites, reduce their interaction with biomolecules, prevent the leakage of toxic components, control their biopersistence, or even introduce stimuli responsiveness.[353] Regulating the position of the valence and conduction band energy levels as well as the bang gap structure might also be an option to avoid the perturbation of cellular redox equilibrium. In addition, changing in their size and structure is an alternative to optimize surface properties and permit rapid elimination from the body. Taking superparamagnetic iron oxide NPs (an excellent contrast agent in MR imaging or hyperthermia agent for PTT) as an example, coating with dextran T-10,[354] dextran,[355] aminosilane,[356] carbohydrate,[357] polystyrene,[358] and siloxane[359] could help to prevent iron release and inhibit iron absorption through interfering with the uptake of iron from the gastrointestinal tract. Therefore, preclinical and clinical studies have been performed to demonstrate the safety and effectiveness of iron oxide NPs as a MR contrast agent in patients[360] (Figure 15). Although the development of safe-by-design nanomedicines has seen significant progress in recent years, this field is still in its infancy and there remain many challenges to be addressed in order to fully promote the concept of safe-by-design into practice. First, although increasing evidence has shown that the toxicities of nanomaterials are directly related to their physicochemical characteristics, the key factors that affect these toxicities and the relationship between properties and biological effects (either desired or not) of nanomaterials are still far from being fully identified. This issue is further complicated by the fact that the tuning of one property by engineering of nanomaterial often leads to the change of many other major properties. For example, coating with silica prevents the release of toxic ions from nanomaterials, yet may also completely change their\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (26 of 33)\nAdv. Mater. 2019, 1805391\nbiological fate; doping nanomaterials with heteroatoms may simultaneously alter their energy band structures (e.g., inhibiting of ROS generation in vivo) and their dissolution (e.g., induction of nanotoxicity). For this reason, nanoinformatic tools may be particularly helpful to map the entire structuretoxicity-function relationship and build predictive models for the safe design of nanomaterials.\nSecond, more effort is needed to close the gap between the research in the principles of nanosafety and nanomaterial science. Examination of the recent literature reveals that the current research on nanomaterials themselves and on their biological effects is still largely independent and only a very limited amount of multidisciplinary study has been established in the nanosafety field. Therefore, further advance of safe-by-design strategies for nanomedicines will call for more extensive and intensive interdisciplinary collaboration and more attention towards the study of nanomaterial-related health risk.\nAnother important is the development of cost-efficient methods for the discovery and engineering of novel nanomedicines. Indeed, the safe-by-design concept serves as a guidance to fabricate safe nanomedicines, but it should not be understood as a guarantee of outcome. Even if safe-by-design nanomedicines are inherently less possible to induce health risks, these risks may not be fully eliminated and their design cannot be completely fail-safe. Most of the previously described safe-by-design approaches mainly focused on the elimination or mitigation of some known toxicities of nanomaterials, and may be ineffective to deal with the unexpected or unknown risks emerged during actual application. Moreover, the complicated individual difference among patients inevitably leads to various adverse effects caused by the same nanomedicine. One of the ultimate goals of safe-by-design nanomedicines is to allow pharmacists and patients to closely monitor the biological effects of nanomaterials and promptly modulate them according to each individual case. We believe that safe-by-design nanomedicines have the potential to bring groundbreaking changes in both medicine and nanotechnology, and we hope that this review will promote the understanding of major principles and challenges in this area, which could in turn be matured and refined\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (27 of 33)\nAdv. Mater. 2019, 1805391\nover time following the accumulation of data on the risks and biological functions of nanomaterials."
    }, {
      "heading" : "Acknowledgements",
      "text" : "L.Y. and F.Z. contributed equally to this work. The authors hereby acknowledge the financial support from the National Basic Research Program of China (Grant No. 2016YFA0201600), the National Natural Science Foundation of China (Grant Nos. 21320102003, 31700866, 51772292, 31571015, 11435002, and 31600815), the Youth Innovation Promotion Association of the Chinese Academy of Sciences (Grant No. 2013007), and Key Research Program of Frontier Sciences (Grant No. QYZDJ-SSW-SLH022).\nConflict of Interest The authors declare no conflict of interest.\nKeywords nanomaterials, nanomedicines, nanotoxicity, principles, safe-by-design\nReceived: August 17, 2018 Revised: September 13, 2018\nPublished online:\n[1] B. S. Pattni, V. V. Chupin, V. P. Torchilin, Chem. Rev. 2015, 115, 10938.\n[2] D. Pedone, M. Moglianetti, E. De Luca, G. Bardi, P. P. Pompa, Chem. Soc. Rev. 2017, 46, 4951. [3] B. Halamoda-Kenzaoui, U. Holzwarth, G. Roebben, A. Bogni, S. Bremer-Hoffmann, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2018, 11, e1531. [4] K. Lu, T. Aung, N. Guo, R. Weichselbaum, W. Bin, Adv. Mater. 2018, 30, 1707634. [5] H. K. Bisoyi, A. M. Urbas, Q. Li, Adv. Opt. Mater. 2018, 6, 1800458. [6] T. Simon-Yarza, A. Mielcarek, P. Couvreur, C. Serre, Adv. Mater.\n2018, 30, 1707365. [7] S. Talebian, J. Foroughi, S. J. Wade, K. L. Vine, A. Dolatshahi-Pirouz,\nM. Mehrali, J. Conde, G. G. Wallace, Adv. Mater. 2018, 30, 1706665. [8] H. Lin, Y. Chen, J. Shi, Chem. Soc. Rev. 2018, 47, 1938. [9] H. Cabral, K. Miyata, K. Osada, K. Kataoka, Chem. Rev. 2018, 118,\n6844. [10] B. Feng, F. Zhou, D. Wang, Z. Xu, H. Yu, Y. Li, Sci. China: Chem.\n2016, 59, 984. [11] A. Gabizon, A. Dagan, D. Goren, Y. Barenholz, Z. Fuks, Cancer Res.\n1982, 42, 4734. [12] A. Gabizon, D. Goren, Z. Fuks, Y. Barenholz, A. Dagan,\nA. Meshorer, Cancer Res. 1983, 43, 4730. [13] Y. Barenholz, J. Controlled Release 2012, 160, 117. [14] X. Chen, S. S. Gambhir, J. Cheon, Acc. Chem. Res. 2011, 44, 841. [15] B. Pelaz, C. Alexiou, R. A. Alvarez-Puebla, F. Alves, A. M. Andrews,\nS. Ashraf, L. P. Balogh, L. Ballerini, A. Bestetti, C. Brendel, S. Bosi, M. Carril, W. C. W. Chan, C. Chen, X. Chen, X. Chen, Z. Cheng, D. Cui, J. Du, C. Dullin, A. Escudero, N. Feliu, M. Gao, M. George, Y. Gogotsi, A. Grünweller, Z. Gu, N. J. Halas, N. Hampp, R. K. Hartmann, M. C. Hersam, P. Hunziker, J. Jian, X. Jiang, P. Jungebluth, P. Kadhiresan, K. Kataoka, A. Khademhosseini, J. Kopeček, N. A. Kotov, H. F. Krug, D. S. Lee, C.-M. Lehr, K. W. Leong, X.-J. Liang, M. Ling Lim, L. M. Liz-Marzán, X. Ma, P. Macchiarini, H. Meng, H. Möhwald, P. Mulvaney,\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (28 of 33)\nAdv. Mater. 2019, 1805391\nA. E. Nel, S. Nie, P. Nordlander, T. Okano, J. Oliveira, T. H. Park, R. M. Penner, M. Prato, V. Puntes, V. M. Rotello, A. Samarakoon, R. E. Schaak, Y. Shen, S. Sjöqvist, A. G. Skirtach, M. G. Soliman, M. M. Stevens, H.-W. Sung, B. Z. Tang, R. Tietze, B. N. Udugama, J. S. VanEpps, T. Weil, P. S. Weiss, I. Willner, Y. Wu, L. Yang, Z. Yue, Q. Zhang, Q. Zhang, X.-E. Zhang, Y. Zhao, X. Zhou, W. J. Parak, ACS Nano 2017, 11, 2313. [16] V. Wagner, A. Dullaart, A.-K. Bock, A. Zweck, Nat. Biotechnol. 2006, 24, 1211. [17] D. Irby, C. Du, F. Li, Mol. Pharmaceutics 2017, 14, 1325. [18] Y. Wang, Q. Zhao, N. Han, L. Bai, J. Li, J. Liu, E. Che, L. Hu,\nQ. Zhang, T. Jiang, S. Wang, Nanomedicine 2015, 11, 313. [19] B. A. Kairdolf, A. M. Smith, T. H. Stokes, M. D. Wang, A. N. Young,\nS. Nie, Annu. Rev. Anal. Chem. 2013, 6, 143. [20] N. Lee, D. Yoo, D. Ling, M. H. Cho, T. Hyeon, J. Cheon, Chem. Rev.\n2015, 115, 10637. [21] Y. Wang, C. Xu, Y. Chang, L. Zhao, K. Zhang, Y. Zhao, F. Gao,\nX. Gao, ACS Appl. Mater. Interfaces 2017, 9, 28959. [22] Z. Gu, L. Yan, G. Tian, S. Li, Z. Chai, Y. Zhao, Adv. Mater. 2013, 25,\n3758. [23] Y. Zu, Y. Yong, X. Zhang, J. Yu, X. Dong, W. Yin, L. Yan, F. Zhao,\nZ. Gu, Y. Zhao, RSC Adv. 2017, 7, 17505. [24] S. Jain, D. G. Hirst, J. M. O’Sullivan, Br. J. Radiol. 2012, 85, 101. [25] R. Zhao, X. Han, Y. Li, H. Wang, T. Ji, Y. Zhao, G. Nie, ACS Nano\n2017, 11, 8103. [26] M. Elsabahy, G. S. Heo, S.-M. Lim, G. Sun, K. L. Wooley, Chem.\nRev. 2015, 115, 10967. [27] L. Gong, L. Yan, R. Zhou, J. Xie, W. Wu, Z. Gu, J. Mater. Chem. B\n2017, 5, 1873. [28] B. Gorain, H. Choudhury, M. Pandey, P. Kesharwani, M. M. Abeer,\nR. K. Tekade, Z. Hussain, Biomed. Pharmacother. 2018, 104, 496. [29] S. R. Shin, Y.-C. Li, H. Jang, P. Khoshakhlagh, M. Akbari, A. Nasajpour, Y. S. Zhang, A. Tamayol, A. Khademhosseini, Adv. Drug Delivery Rev. 2016, 105, 255. [30] According to a search for the term “Nanomedicine” using http:// isiknowledge.com on 5 July 2018. [31] According to a search for “nanotechnology or nanomaterial or nano particle or nanocrystals” using http://worldwide.espacenet. com on 5 July 2018. [32] According to a search for “nanotechnology or nanomaterial or nanoparticle or nanocrystals or nanomedicine” using https://clinicaltrials. gov on 5 July 2018. [33] S. Sharifi, S. Behzadi, S. Laurent, M. L. Forrest, P. Stroeve, M. Mahmoudi, Chem. Soc. Rev. 2012, 41, 2323. [34] Y. Wang, A. Santos, A. Evdokiou, D. Losic, J. Mater. Chem. B 2015, 3, 7153. [35] S. Mukhopadhyay, J. Nautiyal, J. Bhatt, S. Durgapal, J. Nanomed. Res. 2017, 6, 00149. [36] Y. Huang, Y. Jin, R. Zhao, Sci. China: Chem. 2016, 59, 1250. [37] A. M. Derfus, W. C. W. Chan, S. N. Bhatia, Nano Lett. 2004, 4, 11. [38] K. Yamashita, Y. Yoshioka, K. Higashisaka, Y. Morishita, T. Yoshida,\nM. Fujimura, H. Kayamuro, H. Nabeshi, T. Yamashita, K. Nagano, Y. Abe, H. Kamada, Y. Kawai, T. Mayumi, T. Yoshikawa, N. Itoh, S. Tsunoda, Y. Tsutsumi, Inflammation 2010, 33, 276. [39] C. Qu, L. Wang, J. He, J. Tan, W. Liu, S. Zhang, C. Zhang, Z. Wang, S. Jiao, S. Liu, G. Jiang, Gene 2012, 493, 9. [40] Y. Liu, Y. Zhao, B. Sun, C. Chen, Acc. Chem. Res. 2013, 46, 702. [41] L. Wang, J.-H. Liu, Z.-M. Song, Y.-X. Yang, A. Cao, Y. Liu, H. Wang,\nSci. China: Chem. 2016, 59, 910. [42] M. Luo, P. Chen, J. Wang, X. Deng, L. Dong, M. Wu, X. Shen, Sci.\nChina: Chem. 2016, 59, 918. [43] Z. Li, Z. Liu, H. Sun, C. Gao, Chem. Rev. 2015, 115, 7046. [44] J. Conde, N. Oliva, Y. Zhang, N. Artzi, Nat. Mater. 2016, 15, 1128.\n[45] J. Gao, M. Sanchez-Purra, H. Huang, S. Wang, Y. Chen, X. Yu, Q. Luo, K. Hamad-Schifferli, S. Liu, Sci. China: Chem. 2017, 60, 1219. [46] F. Zhao, H. Meng, L. Yan, B. Wang, Y. Zhao, Sci. Bull. 2015, 60, 3. [47] C. Fu, T. Liu, L. Li, H. Liu, D. Chen, F. Tang, Biomaterials 2013, 34,\n2565. [48] S. Ravindran, J. K. Suthar, R. Rokade, P. Deshpande, P. Singh,\nA. Pratinidhi, R. Khambadkhar, S. Utekar, Curr. Drug Metab. 2018, 19, 327. [49] L. Wang, L. Yan, J. Liu, C. Chen, Y. Zhao, Anal. Chem. 2018, 90, 589. [50] C. Chen, Y. Li, Y. Qu, Z. Chai, Y. Zhao, Chem. Soc. Rev. 2013, 42,\n8266. [51] A. M. Alkilany, S. E. Lohse, C. J. Murphy, Acc. Chem. Res. 2013, 46,\n650. [52] I. Lynch, C. Weiss, E. Valsami-Jones, Nano Today 2014, 9, 266. [53] A. E. Nel, L. Mädler, D. Velegol, T. Xia, E. M. V. Hoek,\nP. Somasundaran, F. Klaessig, V. Castranova, M. Thompson, Nat. Mater. 2009, 8, 543. [54] X. Liu, R. Tang, Drug Delivery 2017, 24, 1. [55] J. Wang, W. A. Quershi, Y. Li, J. Xu, G. Nie, Sci. China: Chem. 2016,\n59, 1467. [56] L. Wang, J. Li, J. Pan, X. Jiang, Y. Ji, Y. Li, Y. Qu, Y. Zhao, X. Wu,\nC. Chen, J. Am. Chem. Soc. 2013, 135, 17359. [57] D. Wang, Y. Li, B. Yang, Acta Chim. Sin. 2013, 71, 782. [58] C. P. Roca, R. Rallo, A. Fernandez, F. Giralt, in Towards Efficient\nDesigning of Safe Nanomaterials: Innovative Merge of Computational Approaches and Experimental Techniques (Eds: J. Leszczynski, T. Puzyn), Royal Society of Chemistry, Cambridge, UK 2012, p. 89. [59] V. Maojo, M. Fritts, D. de la Iglesia, R. E. Cachau, M. Garcia-Remesal, J. A. Mitchell, C. Kulikowski, Int. J. Nanomed. 2012, 7, 3867. [60] B. Kim, G. Han, B. Toley, C.-k. Kim, V. M. Rotello, N. S. Forbes, Nat. Nanotechnol. 2010, 5, 465. [61] L. Huynh, C. Neale, R. Pomès, C. Allen, Nanomedicine 2012, 8, 20. [62] V. V. Kleandrova, F. Luan, H. González-Díaz, J. M. Ruso,\nA. Speck-Planche, M. N. D. S. Cordeiro, Environ. Sci. Technol. 2014, 48, 14686. [63] E. Burello, Environ. Sci.: Nano 2015, 2, 454. [64] M. P. Holsapple, W. H. Farland, T. D. Landry, N. A. Monteiro-Riviere,\nJ. M. Carter, N. J. Walker, K. V. Thomas, Toxicol. Sci. 2005, 88, 12. [65] A. Cherkasov, E. N. Muratov, D. Fourches, A. Varnek, I. I. Baskin,\nM. Cronin, J. Dearden, P. Gramatica, Y. C. Martin, R. Todeschini, V. Consonni, V. E. Kuz’min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard, A. Tropsha, J. Med. Chem. 2014, 57, 4977. [66] V. Paramasivam, T. S. Yee, S. K. Dhillon, A. S. Sidhu, Biocybern. Biomed. Eng. 2014, 34, 139. [67] S. Kar, A. Gajewicz, T. Puzyn, K. Roy, Toxicol. In Vitro 2014, 28, 600. [68] R. Liu, R. Rallo, M. Bilal, Y. Cohen, Comb. Chem. High Throughput\nScreening 2015, 18, 365. [69] Y. Pan, T. Li, J. Cheng, D. Telesca, J. I. Zink, J. Jiang, RSC Adv. 2016,\n6, 25766. [70] T. X. Trinh, J.-S. Choi, H. Jeon, H.-G. Byun, T.-H. Yoon, J. Kim,\nChem. Res. Toxicol. 2018, 31, 183. [71] D. Movia, V. Gerard, C. M. Maguire, N. Jain, A. P. Bell, V. Nicolosi,\nT. O’Neill, D. Scholz, Y. Gun’ko, Y. Volkov, A. Prina-Mello, Biomaterials 2014, 35, 2543. [72] I. van de Poel, Z. Robaey, NanoEthics 2017, 11, 297. [73] S. Lin, T. Yu, Z. Yu, X. Hu, D. Yin, Adv. Mater. 2018, 30, 1705691. [74] L. Yan, F. Zhao, S. Li, Z. Hu, Y. Zhao, Nanoscale 2011, 3, 362. [75] A. Nel, T. Xia, H. Meng, X. Wang, S. Lin, Z. Ji, H. Zhang, Acc.\nChem. Res. 2013, 46, 607. [76] C. Ge, J. Du, L. Zhao, L. Wang, Y. Liu, D. Li, Y. Yang, R. Zhou,\nY. Zhao, Z. Chai, C. Chen, Proc. Natl. Acad. Sci. USA 2011, 108, 16968.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (29 of 33)\nAdv. Mater. 2019, 1805391\n[77] A. B. Engin, D. Nikitovic, M. Neagu, P. Henrich-Noack, A. O. Docea, M. I. Shtilman, K. Golokhvast, A. M. Tsatsakis, Part. Fibre Toxicol. 2017, 14, 22. [78] A. D. Bangham, R. W. Horne, J. Mol. Biol. 1964, 8, 660. [79] N. Grimaldi, F. Andrade, N. Segovia, L. Ferrer-Tasies, S. Sala,\nJ. Veciana, N. Ventosa, Chem. Soc. Rev. 2016, 45, 6520. [80] N. Lamichhane, T. S. Udayakumar, W. D. D’Souza, C. B. Simone,\n2nd, S. R. Raghavan , J. Polf, J. Mahmood, Molecules 2018, 23, 288. [81] Y. Lee, D. H. Thompson, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2017, 9, e1450. [82] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Controlled Release 2015, 200, 138. [83] H. Chang, M. Yeh, Int. J. Nanomed. 2012, 7, 49. [84] L. Sercombe, T. Veerati, F. Moheimani, S. Y. Wu, A. K. Sood,\nS. Hua, Front. Pharmacol. 2015, 6, 286. [85] J. Khandare, M. Calderon, N. M. Dagia, R. Haag, Chem. Soc. Rev.\n2012, 41, 2824. [86] G. A. A. Saracino, D. Cigognini, D. Silva, A. Caprini, F. Gelain,\nChem. Soc. Rev. 2013, 42, 225. [87] L. Wang, H. Zhang, A. Qin, Q. Jin, B. Z. Tang, J. Ji, Sci. China:\nChem. 2016, 59, 1609. [88] W. A. Qureshi, R. Zhao, H. Wang, T. Ji, Y. Ding, A. Ihsan,\nA. Mujeeb, G. Nie, Y. Zhao, Sci. Bull. 2016, 61, 1689. [89] D. E. Owens, N. A. Peppas, Int. J. Pharm. 2006, 307, 93. [90] N. Nishiyama, K. Kataoka, Pharmacol. Ther. 2006, 112, 630. [91] D. A. Tomalia, Soft Matter 2010, 6, 456. [92] B. Daglar, E. Ozgur, M. E. Corman, L. Uzun, G. B. Demirel, RSC\nAdv. 2014, 4, 48639. [93] S. K. Shukla, S. K. Shukla, P. P. Govender, N. G. Giri, RSC Adv.\n2016, 6, 94325. [94] R. Tong, J. Cheng, Polym. Rev. 2007, 47, 345. [95] C. C. I. Crucho, ChemMedChem 2015, 10, 24. [96] R. Tong, J. Cheng, Macromolecules 2012, 45, 2225. [97] T. Lammers, V. Subr, K. Ulbrich, W. E. Hennink, G. Storm,\nF. Kiessling, Nano Today 2010, 5, 197. [98] T. Ji, Y. Zhao, Y. Ding, J. Wang, R. Zhao, J. Lang, H. Qin, X. Liu, Shi,\nN. Tao , Z. Qin, G. Nie, Y. Zhao, Angew. Chem., Int. Ed. 2016, 55, 1050. [99] V. Kumar, S. Palazzolo, S. Bayda, G. Corona, G. Toffoli, F. Rizzolio, Theranostics 2016, 6, 710. [100] T. A. P. F. Doll, T. Neef, N. Duong, D. E. Lanar, P. Ringler, S. A. Müller, P. Burkhard, Nanomedicine 2015, 11, 1705. [101] J. Verma, S. Lal, C. J. F. Van Noorden, Eur. J. Nanomed. 2015, 7, 271. [102] J. J. Giner-Casares, M. Henriksen-Lacey, M. Coronado-Puchau, L. M. Liz-Marzán, Mater. Today 2016, 19, 19. [103] L. Li, H. Liu, Nanomedicine 2017, 12, 959. [104] X. Zheng, J. Shi, Y. Bu, G. Tian, X. Zhang, W. Yin, B. Gao,\nZ. Yang, Z. Hu, X. Liu, L. Yan, Z. Gu, Y. Zhao, Nanoscale 2015, 7, 12581. [105] J. Du, X. Zheng, Y. Yong, J. Yu, X. Dong, C. Zhang, R. Zhou, B. Li, L. Yan, C. Chen, Z. Gu, Y. Zhao, Nanoscale 2017, 9, 8229. [106] C. T. Matea, T. Mocan, F. Tabaran, T. Pop, O. Mosteanu, C. Puia, C. Iancu, L. Mocan, Int. J. Nanomed. 2017, 12, 5421. [107] C. Wang, L. Cheng, Z. Liu, Biomaterials 2011, 32, 1110. [108] J. E. Lee, N. Lee, H. Kim, J. Kim, S. H. Choi, J. H. Kim, T. Kim,\nI. C. Song, S. P. Park, W. K. Moon, T. Hyeon, J. Am. Chem. Soc. 2010, 132, 552. [109] J. A. Webb, R. Bardhan, Nanoscale 2014, 6, 2502. [110] E. Locatelli, I. Monaco, M. Comes Franchini, RSC Adv. 2015, 5, 21681. [111] C. Yang, C. Guo, W. Guo, X. Zhao, S. Liu, X. Han, ACS Appl. Nano Mater. 2018, 1, 820. [112] N. Erathodiyil, J. Y. Ying, Acc. Chem. Res. 2011, 44, 925.\n[113] R. Thiruppathi, S. Mishra, M. Ganapathy, P. Padmanabhan, B. Gulyás, Adv. Sci. 2017, 4, 1600279. [114] B. Pelaz, P. del Pino, P. Maffre, R. Hartmann, M. Gallego, S. Rivera-Fernández, J. M. de la Fuente, G. U. Nienhaus, W. J. Parak, ACS Nano 2015, 9, 6996. [115] M. Jiao, P. Zhang, J. Meng, Y. Li, C. Liu, X. Luo, M. Gao, Biomater. Sci. 2018, 6, 726. [116] C. Cha, S. R. Shin, N. Annabi, M. R. Dokmeci, A. Khademhosseini, ACS Nano 2013, 7, 2891. [117] Y. Zhang, D. Petibone, Y. Xu, M. Mahmood, A. Karmakar, D. Casciano, S. Ali, A. S. Biris, Drug Metab. Rev. 2014, 46, 232. [118] F. Du, J. Xu, F. Zeng, S. Wu, Acta Chim. Sin. 2016, 74, 241. [119] C. Y. Chen, G. M. Xing, J. X. Wang, Y. L. Zhao, B. Li, J. Tang, G. Jia,\nT. C. Wang, J. Sun, L. Xing, H. Yuan, Y. X. Gao, H. Meng, Z. Chen, F. Zhao, Z. F. Chai, X. H. Fang, Nano Lett. 2005, 5, 2050. [120] H.-C. Wu, X. Chang, L. Liu, F. Zhao, Y. Zhao, J. Mater. Chem. 2010, 20, 1036. [121] J. Park, M. Yan, Acc. Chem. Res. 2013, 46, 181. [122] G. Reina, J. M. Gonzalez-Dominguez, A. Criado, E. Vazquez,\nA. Bianco, M. Prato, Chem. Soc. Rev. 2017, 46, 4400. [123] H. Meng, G. Xing, E. Blanco, Y. Song, L. Zhao, B. Sun, X. Li,\nP. C. Wang, A. Korotcov, W. Li, X. Liang, C. Chen, H. Yuan, F. Zhao, Z. Chen, T. Sun, Z. Chai, M. Ferrari, Y. Zhao, Nanomedicine 2012, 8, 136. [124] J. Meng, X. J. Liang, X. Y. Chen, Y. L. Zhao, Integr. Biol. 2013, 5, 43. [125] Y. Liu, C. Y. Chen, P. X. Qian, X. F. Lu, B. Y. Sun, X. Zhang,\nL. M. Wang, X. F. Gao, H. Li, Z. Y. Chen, J. L. Tang, W. J. Zhang, J. Q. Dong, R. Bai, P. E. Lobie, Q. F. Wu, S. L. Liu, H. F. Zhang, F. Zhao, M. S. Wicha, T. Zhu, Y. L. Zhao, Nat. Commun. 2015, 6, 5988. [126] Y. Pan, L. Wang, S. Kang, Y. Lu, Z. Yang, H. Tien, C. Chen, R. Zhou, M. Guo, Y. Zhao, ACS Nano 2015, 9, 6826. [127] M. Bottini, N. Rosato, N. Bottini, Biomacromolecules 2011, 12, 3381. [128] K. Yang, L. Feng, X. Shi, Z. Liu, Chem. Soc. Rev. 2013, 42, 530. [129] K. Yang, L. Feng, Z. Liu, Adv. Drug Delivery Rev. 2016, 105, 228. [130] G. Hong, S. Diao, A. L. Antaris, H. Dai, Chem. Rev. 2015, 115, 10816. [131] Z. Zhu, Z. Tang, J. A. Phillips, R. Yang, H. Wang, W. Tan, J. Am. Chem. Soc. 2008, 130, 10856. [132] W. Park, S.-J. Park, S. Cho, H. Shin, Y.-S. Jung, B. Lee, K. Na, D.-H. Kim, J. Am. Chem. Soc. 2016, 138, 10734. [133] K. Bhattacharya, S. P. Mukherjee, A. Gallud, S. C. Burkert,\nS. Bistarelli, S. Bellucci, M. Bottini, A. Star, B. Fadeel, Nanomedicine 2016, 12, 333. [134] P. R. Leroueil, S. A. Berry, K. Duthie, G. Han, V. M. Rotello, D. Q. McNerny, J. R. Baker, B. G. Orr, M. M. Banaszak Holl, Nano Lett. 2008, 8, 420. [135] E. Navarro, A. Baun, R. Behra, N. B. Hartmann, J. Filser, A.-J. Miao, A. Quigg, P. H. Santschi, L. Sigg, Ecotoxicology 2008, 17, 372. [136] J. Øvrevik, M. Låg, P. Schwarze, M. Refsnes, Toxicol. Sci. 2004, 81, 480. [137] Y. H. Leung, X. Xu, A. P. Y. Ma, F. Liu, A. M. C. Ng, Z. Shen, L. A. Gethings, M. Y. Guo, A. B. Djurišić, P. K. H. Lee, H. K. Lee, W. K. Chan, F. C. C. Leung, Sci. Rep. 2016, 6, 35243. [138] H. Nagai, Y. Okazaki, S. H. Chew, N. Misawa, Y. Yamashita, S. Akatsuka, T. Ishihara, K. Yamashita, Y. Yoshikawa, H. Yasui, L. Jiang, H. Ohara, T. Takahashi, G. Ichihara, K. Kostarelos, Y. Miyata, H. Shinohara, S. Toyokuni, Proc. Natl. Acad. Sci. 2011, 108, E1330. [139] O. Akhavan, E. Ghaderi, ACS Nano 2010, 4, 5731. [140] Y. Tu, M. Lv, P. Xiu, T. Huynh, M. Zhang, M. Castelli, Z. Liu,\nQ. Huang, C. Fan, H. Fang, R. Zhou, Nat. Nanotechnol. 2013, 8, 594.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (30 of 33)\nAdv. Mater. 2019, 1805391\n[141] X. Liu, K. L. Chen, Langmuir 2015, 31, 12076. [142] G. Duan, Y. Zhang, B. Luan, J. K. Weber, R. W. Zhou, Z. Yang,\nL. Zhao, J. Xu, J. Luo, R. Zhou, Sci. Rep. 2017, 7, 42767. [143] S. C. Sahu, A. W. Hayes, Toxicol. Res. Appl. 2017, 1,\n239784731772635. [144] B. Dogan-Topal, B. Uslu, S. A. Ozkan, in Nanoscale Fabrica-\ntion, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology (Ed: A. M. Grumezescu), William Andrew, Norwich, UK 2018, p. 547. [145] F. M. Winnik, D. Maysinger, Acc. Chem. Res. 2013, 46, 672. [146] L. M. Sargent, A. F. Hubbs, S. H. Young, M. L. Kashon, C. Z. Dinu,\nJ. L. Salisbury, S. A. Benkovic, D. T. Lowry, A. R. Murray, E. R. Kisin, K. J. Siegrist, L. Battelli, J. Mastovich, J. L. Sturgeon, K. L. Bunker, A. A. Shvedova, S. H. Reynolds, Mutat. Res., Genet. Toxicol. Environ. Mutagen. 2012, 745, 28. [147] I. Nabiev, S. Mitchell, A. Davies, Y. Williams, D. Kelleher, R. Moore, Y. K. Gun’ko, S. Byrne, Y. P. Rakovich, J. F. Donegan, A. Sukhanova, J. Conroy, D. Cottell, N. Gaponik, A. Rogach, Y. Volkov, Nano Lett. 2007, 7, 3452. [148] C. Gong, G. Tao, L. Yang, J. Liu, Q. Liu, Z. Zhuang, Biochem. Biophys. Res. Commun. 2010, 397, 397. [149] K. H. Park, M. Chhowalla, Z. Iqbal, F. Sesti, J. Biol. Chem. 2003, 278, 50212. [150] S. J. Soenen, N. Nuytten, S. F. De Meyer, S. C. De Smedt, M. De Cuyper, Small 2010, 6, 832. [151] B. D. Holt, P. A. Short, A. D. Rape, Y.-l. Wang, M. F. Islam, K. N. Dahl, ACS Nano 2010, 4, 4872. [152] D. Öner, M. Moisse, M. Ghosh, R. C. Duca, K. Poels, K. Luyts, E. Putzeys, S. M. Cokic, K. Van Landuyt, J. Vanoirbeek, D. Lambrechts, L. Godderis, P. H. M. Hoet, Mutagenesis 2017, 32, 181. [153] A. O. Choi, S. E. Brown, M. Szyf, D. Maysinger, J. Mol. Med. 2008, 86, 291. [154] M. Hadjidemetriou, K. Kostarelos, Nat. Nanotechnol. 2017, 12, 288. [155] D. Docter, D. Westmeier, M. Markiewicz, S. Stolte, S. K. Knauer, R. H. Stauber, Chem. Soc. Rev. 2015, 44, 6094. [156] C. Ge, J. Tian, Y. Zhao, C. Chen, R. Zhou, Z. Chai, Arch. Toxicol. 2015, 89, 519. [157] X. Cheng, X. Tian, A. Wu, J. Li, J. Tian, Y. Chong, Z. Chai, Y. Zhao, C. Chen, C. Ge, ACS Appl. Mater. Interfaces 2015, 7, 20568. [158] Z. J. Deng, M. Liang, M. Monteiro, I. Toth, R. F. Minchin, Nat. Nanotechnol. 2011, 6, 39. [159] Y.-N. Chang, M. Zhang, L. Xia, J. Zhang, G. Xing, Materials 2012, 5, 2850. [160] Z. Chen, Y. Liu, B. Sun, H. Li, J. Dong, L. Zhang, L. Wang, P. Wang, Y. Zhao, C. Chen, Small 2014, 10, 2362. [161] V. Mailänder, K. Landfester, Biomacromolecules 2009, 10, 2379. [162] P. Wang, X. Nie, Y. Wang, Y. Li, C. Ge, L. Zhang, L. Wang, R. Bai, Z. Chen, Y. Zhao, C. Chen, Small 2013, 9, 3799. [163] B. Sun, X. Wang, Z. Ji, R. Li, T. Xia, Small 2013, 9, 1595. [164] M. A. Dobrovolskaia, D. R. Germolec, J. L. Weaver, Nat. Nanotechnol. 2009, 4, 411. [165] B. Barna, M. Judson, M. Thomassen, Nanomaterials 2014, 4, 508. [166] J. P. Ryman-Rasmussen, M. F. Cesta, A. R. Brody, J. K. Shipley-Phillips,\nJ. Everitt, E. W. Tewksbury, O. R. Moss, B. A. Wong, D. E. Dodd, M. E. Andersen, J. C. Bonner, Nat. Nanotechnol. 2009, 4, 747. [167] C. Y. Tay, P. Cai, M. I. Setyawati, W. Fang, L. P. Tan, C. H. L. Hong, X. Chen, D. T. Leong, Nano Lett. 2014, 14, 83. [168] M. I. Setyawati, C. Sevencan, B. H. Bay, J. Xie, Y. Zhang, P. Demokritou, D. T. Leong, Small 2018, 14, 1800922. [169] L. Wang, T. Zhang, P. Li, W. Huang, J. Tang, P. Wang, J. Liu, Q. Yuan, R. Bai, B. Li, K. Zhang, Y. Zhao, C. Chen, ACS Nano 2015, 9, 6532.\n[170] Y. Su, M. Hu, C. Fan, Y. He, Q. Li, W. Li, L.-H. Wang, P. Shen, Q. Huang, Biomaterials 2010, 31, 4829. [171] L. Xia, W. Gu, M. Zhang, Y.-N. Chang, K. Chen, X. Bai, L. Yu, J. Li, S. Li, G. Xing, Part. Fibre Toxicol. 2016, 13, 63. [172] Y.-Y. Tsai, Y.-H. Huang, Y.-L. Chao, K.-Y. Hu, L.-T. Chin, S.-H. Chou, A.-L. Hour, Y.-D. Yao, C.-S. Tu, Y.-J. Liang, C.-Y. Tsai, H.-Y. Wu, S.-W. Tan, H.-M. Chen, ACS Nano 2011, 5, 9354. [173] S. Zhang, S. Chen, C. Gao, Y. Jin, G. Jia, Z. Li, D. Liu, X. Liang, X. Yang, J. Zhang, Sci. China: Chem. 2017, 60, 122. [174] L. Huo, R. Chen, L. Zhao, X. Shi, R. Bai, D. Long, F. Chen, Y. Zhao, Y. Chang, C. Chen, Biomaterials 2015, 61, 307. [175] S. T. Stern, P. P. Adiseshaiah, R. M. Crist, Part. Fibre Toxicol. 2012, 9, 20. [176] V. Cohignac, M. Landry, J. Boczkowski, S. Lanone, Nanomaterials 2014, 4, 548. [177] P. P. Fu, Q. Xia, H. M. Hwang, P. C. Ray, H. Yu, J. Food Drug Anal. 2014, 22, 64. [178] L. Yan, Z. Gu, Y. Zhao, Chem. Asian J. 2013, 8, 2342. [179] S. J. Soenen, P. Rivera-Gil, J.-M. Montenegro, W. J. Parak,\nS. C. De Smedt, K. Braeckmans, Nano Today 2011, 6, 446. [180] A. Abdal Dayem, M. K. Hossain, S. B. Lee, K. Kim, S. K. Saha,\nG. M. Yang, H. Y. Choi, S. G. Cho, Int. J. Mol. Sci. 2017, 18, 120. [181] W. Zhang, L. Yan, M. Li, R. Zhao, X. Yang, T. Ji, Z. Gu, J.-J. Yin, X. Gao, G. Nie, Toxicol. Lett. 2015, 237, 61. [182] W. Wu, L. Yan, S. Chen, Q. Li, Z. Gu, H. Xu, Z. Q. Yin, Nanotoxicology 2018, 12, 819. [183] M. I. Setyawati, C. Y. Tay, B. H. Bay, D. T. Leong, ACS Nano 2017, 11, 5020. [184] J. Wang, L. Zhang, F. Peng, X. Shi, D. T. Leong, Chem. Mater. 2018, 30, 3759. [185] M. I. Setyawati, V. N. Mochalin, D. T. Leong, ACS Nano 2016, 10, 1170. [186] K. P. Loh, D. Ho, G. N. C. Chiu, D. T. Leong, G. Pastorin, E. K.-H. Chow, Adv. Mater. 2018, 30, 1802368. [187] M. L. Chua, M. I. Setyawati, H. Li, C. H. Y. Fang, S. Gurusamy, F. T. L. Teoh, D. T. Leong, S. George, Indoor Air 2017, 27, 551. [188] C. Y. Tay, M. I. Setyawati, D. T. Leong, ACS Nano 2017, 11, 2764. [189] G.-Y. Chen, C.-L. Chen, H.-Y. Tuan, P.-X. Yuan, K.-C. Li, H.-J. Yang, Y.-C. Hu, Adv. Healthcare Mater. 2014, 3, 1486. [190] A. Guerrero-Martinez, J. Perez-Juste, L. M. Liz-Marzan, Adv. Mater. 2010, 22, 1182. [191] U. Wais, A. W. Jackson, T. He, H. Zhang, Nanoscale 2016, 8, 1746. [192] S. L. Chia, D. T. Leong, Heliyon 2016, 2, e00177. [193] D. Giaume, M. Poggi, D. Casanova, G. Mialon, K. Lahlil, A. Alexandrou, T. Gacoin, J.-P. Boilot, Langmuir 2008, 24, 11018. [194] B. A. Moser, R. C. Steinhardt, A. P. Esser-Kahn, ACS Biomater. Sci. Eng. 2017, 3, 206. [195] Y. Ma, Y. Li, S. Ma, X. Zhong, J. Mater. Chem. B 2014, 2, 5043. [196] A. Wolcott, D. Gerion, M. Visconte, J. Sun, A. Schwartzberg, S. Chen, J. Z. Zhang, J. Phys. Chem. B 2006, 110, 5779. [197] H. L. Ding, Y. X. Zhang, S. Wang, J. M. Xu, S. C. Xu, G. H. Li, Chem. Mater. 2012, 24, 4572. [198] L. Yan, Y. B. Zheng, F. Zhao, S. Li, X. Gao, B. Xu, P. S. Weiss, Y. Zhao, Chem. Soc. Rev. 2012, 41, 97. [199] X. Liu, L. Yan, W. Yin, L. Zhou, G. Tian, J. Shi, Z. Yang, D. Xiao, Z. Gu, Y. Zhao, J. Mater. Chem. A 2014, 2, 12296. [200] M. Tejamaya, I. Römer, R. C. Merrifield, J. R. Lead, Environ. Sci. Technol. 2012, 46, 7011. [201] S. Tong, S. Hou, B. Ren, Z. Zheng, G. Bao, Nano Lett. 2011, 11, 3720. [202] S. M. Chowdhury, C. Surhland, Z. Sanchez, P. Chaudhary,\nM. A. S. Kumar, S. Lee, L. A. Peña, M. Waring, B. Sitharaman, M. Naidu, Nanomedicine 2015, 11, 109.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (31 of 33)\nAdv. Mater. 2019, 1805391\n[203] C. D. Fahrenholtz, M. Hadimani, S. B. King, S. V. Torti, R. Singh, Nanomedicine 2015, 10, 2481. [204] T. Gong, J. Xie, J. Liao, T. Zhang, S. Lin, Y. Lin, Bone Res. 2015, 3, 15029. [205] S. Pina, J. M. Oliveira, R. L. Reis, Adv. Mater. 2015, 27, 1143. [206] V. Georgakilas, M. Otyepka, A. B. Bourlinos, V. Chandra, N. Kim,\nK. C. Kemp, P. Hobza, R. Zboril, K. S. Kim, Chem. Rev. 2012, 112, 6156. [207] S. Presolski, M. Pumera, Mater. Today 2016, 19, 140. [208] Q. He, D. O. Kiesewetter, Y. Qu, X. Fu, J. Fan, P. Huang, Y. Liu, G. Zhu, Y. Liu, Z. Qian, X. Chen, Adv. Mater. 2015, 27, 6741. [209] Z. Du, R. Dou, M. Zu, X. Liu, W. Yin, Y. Zhao, J. Chen, L. Yan, Z. Gu, Biomater. Sci. 2016, 4, 938. [210] J. C. Yu, J. Yu, W. Ho, Z. Jiang, L. Zhang, Chem. Mater. 2002, 14, 3808. [211] H. Naatz, S. Lin, R. Li, W. Jiang, Z. Ji, C. H. Chang, J. Köser,\nJ. Thöming, T. Xia, A. E. Nel, L. Mädler, S. Pokhrel, ACS Nano 2017, 11, 501. [212] J. Schneider, M. Matsuoka, M. Takeuchi, J. Zhang, Y. Horiuchi, M. Anpo, D. W. Bahnemann, Chem. Rev. 2014, 114, 9919. [213] J. Low, J. Yu, M. Jaroniec, S. Wageh, A. A. Al-Ghamdi, Adv. Mater. 2017, 29, 1601694. [214] M. Ahamed, M. A. M. Khan, M. J. Akhtar, H. A. Alhadlaq, A. Alshamsan, Sci. Rep. 2016, 6, 30196. [215] L. Yan, Z. Gu, X. Zheng, C. Zhang, X. Li, L. Zhao, Y. Zhao, ACS Catal. 2017, 7, 7043. [216] C. Zhang, Z. Du, R. Zhou, P. Xu, X. Dong, Y. Fu, Q. Wang, C. Su, L. Yan, Z. Gu, RSC Adv. 2018, 8, 3611. [217] E. J. Keliher, Y.-X. Ye, G. R. Wojtkiewicz, A. D. Aguirre, B. Tricot, M. L. Senders, H. Groenen, F. Fay, C. Perez-Medina, C. Calcagno, G. Carlucci, T. Reiner, Y. Sun, G. Courties, Y. Iwamoto, H.-Y. Kim, C. Wang, J. W. Chen, F. K. Swirski, H.-Y. Wey, J. Hooker, Z. A. Fayad, W. J. M. Mulder, R. Weissleder, M. Nahrendorf, Nat. Commun. 2017, 8, 14064. [218] S.-T. Yang, J. Luo, Q. Zhou, H. Wang, Theranostics 2012, 2, 271. [219] T. Sakai, H. Kohno, T. Ishihara, M. Higaki, S. Saito,\nM. Matsushima, Y. Mizushima, K. Kitahara, Exp. Eye Res. 2006, 82, 657.\n[220] X. Duan, Y. Li, Small 2013, 9, 1521. [221] L. Tang, X. Yang, Q. Yin, K. Cai, H. Wang, I. Chaudhury, C. Yao,\nQ. Zhou, M. Kwon, J. A. Hartman, I. T. Dobrucki, L. W. Dobrucki, L. B. Borst, S. Lezmi, W. G. Helferich, A. L. Ferguson, T. M. Fan, J. Cheng, Proc. Natl. Acad. Sci. USA 2014, 111, 15344. [222] E. A. Sykes, Q. Dai, C. D. Sarsons, J. Chen, J. V. Rocheleau, D. M. Hwang, G. Zheng, D. T. Cramb, K. D. Rinker, W. C. W. Chan, Proc. Natl. Acad. Sci. USA 2016, 113, 1142. [223] E. A. Sykes, J. Chen, G. Zheng, W. C. W. Chan, ACS Nano 2014, 8, 5696. [224] H. Wang, R. F. Zhao, Y. Y. Li, H. Y. Liu, F. Li, Y. L. Zhao, G. J. Nie, Nanomedicine 2016, 12, 439. [225] R. A. Petros, J. M. DeSimone, Nat. Rev. Drug Discovery 2010, 9, 615. [226] J. A. Copland, M. Eghtedari, V. L. Popov, N. Kotov, N. Mamedova, M. Motamedi, A. A. Oraevsky, Mol. Imaging Biol. 2004, 6, 341. [227] P. K. Jain, K. S. Lee, I. H. El-Sayed, M. A. El-Sayed, J. Phys. Chem. B 2006, 110, 7238. [228] M. R. K. Ali, M. A. Rahman, Y. Wu, T. Han, X. Peng, M. A. Mackey, D. Wang, H. J. Shin, Z. G. Chen, H. Xiao, R. Wu, Y. Tang, D. M. Shin, M. A. El-Sayed, Proc. Natl. Acad. Sci. 2017, 114, 3110. [229] Y. Wang, K. C. L. Black, H. Luehmann, W. Li, Y. Zhang, X. Cai, D. Wan, S.-Y. Liu, M. Li, P. Kim, Z.-Y. Li, L. V. Wang, Y. Liu, Y. Xia, ACS Nano 2013, 7, 2068. [230] E. Burello, A. P. Worth, Nanotoxicology 2011, 5, 228. [231] E. Burello, A. P. Enrico, Wiley Interdiscip. Rev.: Nanomed. Nanobio-\ntechnol. 2011, 3, 298.\n[232] H. Zhang, Z. Ji, T. Xia, H. Meng, C. Low-Kam, R. Liu, S. Pokhrel, S. Lin, X. Wang, Y.-P. Liao, M. Wang, L. Li, R. Rallo, R. Damoiseaux, D. Telesca, L. Madler, Y. Cohen, J. I. Zink, A. E. Nel, ACS Nano 2012, 6, 4349. [233] L. Maggiorella, G. Barouch, C. Devaux, A. Pottier, E. Deutsch, J. Bourhis, E. Borghi, L. Levy, Future Oncol. 2012, 8, 1167. [234] M. W. Ahmad, W. Xu, S. J. Kim, J. S. Baeck, Y. Chang, J. E. Bae, K. S. Chae, J. A. Park, T. J. Kim, G. H. Lee, Sci. Rep. 2015, 5, 8549. [235] S. Kohei, T. Kimikazu, T. Kosuke, Y. Tomoyoshi, H. Hiroshi, K. Hidehiro, Eur. J. Inorg. Chem. 2010, 2010, 2673. [236] W. Feng, X. Zhu, F. Li, NPG Asia Mater. 2013, 5, e75. [237] N. Hao, L. Li, F. Tang, Biomater. Sci. 2016, 4, 575. [238] H. Y. Zhang, S. Pokhrel, Z. X. Ji, H. Meng, X. Wang, S. J. Lin,\nC. H. Chang, L. J. Li, R. B. Li, B. B. Sun, M. Y. Wang, Y. P. Liao, R. Liu, T. Xia, L. Madler, A. E. Nel, J. Am. Chem. Soc. 2014, 136, 6406.\n[239] Y. Cheng, Y. Chang, Y. Feng, H. Jian, Z. Tang, H. Zhang, Angew. Chem. Int. Ed. 2018, 57, 246. [240] Y. Li, W. Zhang, J. Niu, Y. Chen, ACS Nano 2012, 6, 5164. [241] S. George, S. Pokhrel, Z. Ji, B. L. Henderson, T. Xia, L. Li, J. I. Zink, A. E. Nel, L. Mädler, J. Am. Chem. Soc. 2011, 133, 11270. [242] P. Maddahi, N. Shahtahmasebi, A. Kompany, M. Mashreghi, S. Safaee, F. Roozban, Mater. Sci. 2014, 32, 130. [243] J. Gupta, D. Bahadur, ACS Omega 2018, 3, 2956. [244] M.-H. Kim, J.-H. Seo, H.-M. Kim, H.-J. Jeong, J. Biomater. Appl. 2016, 30, 1407. [245] J. Zhou, Z. Liu, F. Li, Chem. Soc. Rev. 2012, 41. 1323. [246] M. N. O’Brien, M. R. Jones, C. A. Mirkin, Proc. Natl. Acad. Sci. USA 2016, 113, 11717. [247] J. Muller, F. Huaux, A. Fonseca, J. B. Nagy, N. Moreau, M. Delos,\nE. Raymundo-Piñero, F. Béguin, M. Kirsch-Volders, I. Fenoglio, B. Fubini, D. Lison, Chem. Res. Toxicol. 2008, 21, 1698. [248] S. George, S. Lin, Z. Ji, C. R. Thomas, L. Li, M. Mecklenburg, H. Meng, X. Wang, H. Zhang, T. Xia, J. N. Hohman, S. Lin, J. I. Zink, P. S. Weiss, A. E. Nel, ACS Nano 2012, 6, 3745. [249] X. Cai, A. Lee, Z. Ji, C. Huang, C. H. Chang, X. Wang, Y.-P. Liao, T. Xia, R. Li, Part. Fibre Toxicol. 2017, 14, 13. [250] G. Kiliç, C. Costa, N. Fernández-Bertólez, E. Pásaro, J. P. Teixeira, B. Laffon, V. Valdiglesias, Toxicol. Res. 2016, 5, 235. [251] X. Wang, M. Wang, R. Lei, S. F. Zhu, Y. Zhao, C. Chen, ACS Nano 2017, 11, 4606. [252] L. Yildirimer, N. T. K. Thanh, M. Loizidou, A. M. Seifalian, Nano Today 2011, 6, 585. [253] R. Hao, R. Xing, Z. Xu, Y. Hou, S. Gao, S. Sun, Adv. Mater. 2010, 22, 2729. [254] S. R. Saptarshi, A. Duschl, A. L. Lopata, J. Nanobiotechnol. 2013, 11, 26. [255] M. Kopp, S. Kollenda, M. Epple, Acc. Chem. Res. 2017, 50, 1383. [256] C. Gunawan, M. Lim, C. P. Marquis, R. Amal, J. Mater. Chem. B 2014, 2, 2060. [257] X. Li, S. M. Robinson, A. Gupta, K. Saha, Z. Jiang, D. F. Moyano, A. Sahar, M. A. Riley, V. M. Rotello, ACS Nano 2014, 8, 10682. [258] R. Gref, M. Lück, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, R. H. Müller, Colloids Surf., B 2000, 18, 301. [259] S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailänder, F. R. Wurm, Nat. Nanotechnol. 2016, 11, 372. [260] S. Salmaso, P. Caliceti, J. Drug Delivery 2013, 2013, 1. [261] S. I. Jeon, J. H. Lee, J. D. Andrade, P. G. De Gennes, J. Colloid Interface Sci. 1991, 142, 149. [262] S. Susanne, L. Katharina, M. Volker, Angew. Chem., Int. Ed. 2016, 55, 8806. [263] J. S. Suk, Q. Xu, N. Kim, J. Hanes, L. M. Ensign, Adv. Drug Delivery Rev. 2016, 99, 28. [264] T. M. Allen, E. H. Moase, Adv. Drug Delivery Rev. 1996, 21, 117. [265] K. R. Reddy, T. L. Wright, P. J. Pockros, M. Shiffman, G. Everson,\nR. Reindollar, M. W. Fried, P. P. 3rd Purdum, D. Jensen, C. Smith,\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (32 of 33)\nW. M. Lee, T. D. Boyer, A. Lin, S. Pedder, J. DePamphilis, Hepatology 2001, 33, 433. [266] P. Ebrahimnejad, R. Dinarvand, M. R. Jafari, S. A. S. Tabasi, F. Atyabi, Int. J. Pharm. 2011, 406, 122. [267] M. Miteva, K. C. Kirkbride, K. V. Kilchrist, T. A. Werfel, H. Li, C. E. Nelson, M. K. Gupta, T. D. Giorgio, C. L. Duvall, Biomaterials 2015, 38, 97. [268] C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. W. Chan, J. Am. Chem. Soc. 2012, 134, 2139. [269] P. Mishra, B. Nayak, R. K. Dey, Asian J. Pharm. Sci. 2016, 11, 337. [270] J. V. Jokerst, T. Lobovkina, R. N. Zare, S. S. Gambhir, Nanomedicine 2011, 6, 715. [271] D. Jain, R. Athawale, A. Bajaj, S. Shrikhande, P. N. Goel, R. P. Gude, Colloids Surf., B 2013, 109, 59. [272] G. da Rocha Lindner, D. Bonfanti Santos, D. Colle,\nE. L. Gasnhar Moreira, R. Daniel Prediger, M. Farina, N. M. Khalil, R. Mara Mainardes, Nanomedicine 2015, 10, 1127.\n[273] Z. Amoozgar, Y. Yeo, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2012, 4, 219. [274] C. Li, S. Wallace, Adv. Drug Delivery Rev. 2008, 60, 886. [275] E. Wenande, L. H. Garvey, Clin. Exp. Allergy 2016, 46, 907. [276] S. Shah, T. Prematta, N. F. Adkinson, F. T. Ishmael, J. Clin. Pharmacol. 2013, 53, 352. [277] P. Wilson, P. C. Ke, T. P. Davis, K. Kempe, Eur. Polym. J. 2017, 88,\n486. [278] G. Wang, Y. Ma, J. Mu, Z. Zhang, X. Zhang, L. Zhang, H. Che, Y. Bai, J. Hou, H. Xie, Appl. Surf. Sci. 2016, 365, 114. [279] I. Lilge, H. Schönherr, Langmuir 2016, 32, 838. [280] K. P. García, K. Zarschler, L. Barbaro, J. A. Barreto, W. O’Malley, L. Spiccia, H. Stephan, B. Graham, Small 2014, 10, 2516. [281] L. L. Ma, P. Jie, S. S. Venkatraman, Adv. Funct. Mater. 2008, 18, 716. [282] R. G. Thorne, C. Nicholson, Proc. Natl. Acad. Sci. USA 2006, 103, 5567. [283] Z. Amoozgar, J. Park, Q. Lin, Y. Yeo, Mol. Pharmaceutics 2012, 9, 1262. [284] X. Han, Z. Li, J. Sun, C. Luo, L. Li, Y. Liu, Y. Du, S. Qiu, X. Ai, C. Wu, H. Lian, Z. He, J. Controlled Release 2015, 197, 29. [285] M. d. P. Rodriguez-Torres, L. S. Acosta-Torres, L. A. Diaz-Torres, J. Nanomater. 2018, 2018, 1. [286] K. Debnath, K. Mandal, N. R. Jana, Langmuir 2016, 32, 2798. [287] J. Mariam, S. Sivakami, P. M. Dongre, Drug Delivery 2016, 23, 2668. [288] H. Ding, Y. Lv, D. Ni, J. Wang, Z. Tian, W. Wei, G. Ma, Nanoscale 2015, 7, 9806. [289] J. D. Zhou, M. Gysell, S. Tara, M. Anthony, M. Darren, F. M. Rodney, Nanotechnology 2009, 20, 455101. [290] N. Hadjesfandiari, A. Parambath, in Engineering of Bioma-\nterial for Drug Delivery Systems: Beyond Polyethylene Glycol (Ed: A. Parambath), Woodhead, Cambridge, UK 2018, p. 345. [291] B. Kang, P. Okwieka, S. Schöttler, O. Seifert, R. E. Kontermann, K. Pfizenmaier, A. Musyanovych, R. Meyer, M. Diken, U. Sahin, V. Mailänder, F. R. Wurm, K. Landfester, Biomaterials 2015, 49, 125. [292] A. Besheer, J. Vogel, D. Glanz, J. Kressler, T. Groth, K. Mäder, Mol. Pharmaceutics 2009, 6, 407. [293] B. Kang, P. Okwieka, S. Schottler, S. Winzen, J. Langhanki, K. Mohr, T. Opatz, V. Mailander, K. Landfester, F. R. Wurm, Angew. Chem. Int. Ed. 2015, 54, 7436. [294] T. V. Duncan, ACS Appl. Mater. Interfaces 2015, 7, 20. [295] S. Park, K.-S. Lee, G. Bozoklu, W. Cai, S. T. Nguyen, R. S. Ruoff, ACS Nano 2008, 2, 572. [296] A. Hashemi, N. Jouault, G. A. Williams, D. Zhao, K. J. Cheng, J. W. Kysar, Z. Guan, S. K. Kumar, Nano Lett. 2015, 15, 5465. [297] T. Ramanathan, A. A. Abdala, S. Stankovich, D. A. Dikin,\nM. Herrera-Alonso, R. D. Piner, D. H. Adamson, H. C. Schniepp,\nX. Chen, R. S. Ruoff, S. T. Nguyen, I. A. Aksay, R. K. Prud’Homme, L. C. Brinson, Nat. Nanotechnol. 2008, 3, 327.\n[298] L. Yan, Y.-N. Chang, W. Yin, X. Liu, D. Xiao, G. Xing, L. Zhao, Z. Gu, Y. Zhao, Phys. Chem. Chem. Phys. 2014, 16, 1576. [299] L. Yan, Y.-N. Chang, W. Yin, G. Tian, L. Zhou, Z. Hu, G. Xing, Z. Gu, Y. Zhao, Adv. Eng. Mater. 2015, 17, 523. [300] Y. Q. Li, T. Yu, T. Y. Yang, L. X. Zheng, K. Liao, Adv. Mater. 2012, 24, 3426. [301] W. Lu, D. Senapati, S. Wang, O. Tovmachenko, A. K. Singh, H. Yu, P. C. Ray, Chem. Phys. Lett. 2010, 487, 92. [302] C. Cametti, I. Fratoddi, I. Venditti, M. V. Russo, Langmuir 2011, 27, 7084. [303] Y.-M. Long, L.-G. Hu, X.-T. Yan, X.-C. Zhao, Q.-F. Zhou, Y. Cai, G.-B. Jiang, Int. J. Nanomed. 2017, 12, 3193. [304] X. Yang, A. P. Gondikas, S. M. Marinakos, M. Auffan, J. Liu, H. Hsu-Kim, J. N. Meyer, Environ. Sci. Technol. 2012, 46, 1119. [305] A. K. Suresh, D. A. Pelletier, W. Wang, J. L. Morrell-Falvey, B. Gu, M. J. Doktycz, Langmuir 2012, 28, 2727. [306] G. A. Sotiriou, C. Watson, K. M. Murdaugh, T. H. Darrah, G. Pyrgiotakis, A. Elder, J. D. Brain, P. Demokritou, Environ. Sci.: Nano 2014, 1, 144. [307] S. George, S. Pokhrel, T. Xia, B. Gilbert, Z. Ji, M. Schowalter, A. Rosenauer, R. Damoiseaux, K. A. Bradley, L. Mädler, A. E. Nel, ACS Nano 2010, 4, 15. [308] T. Xia, Y. Zhao, T. Sager, S. George, S. Pokhrel, N. Li, D. Schoenfeld, H. Meng, S. Lin, X. Wang, M. Wang, Z. Ji, J. I. Zink, L. Mädler, V. Castranova, S. Lin, A. E. Nel, ACS Nano 2011, 5, 1223. [309] M. J. Akhtar, H. A. Alhadlaq, A. Alshamsan, M. A. Majeed Khan, M. Ahamed, Sci. Rep. 2015, 5, 13876. [310] T. Walser, L. K. Limbach, R. Brogioli, E. Erismann, L. Flamigni, B. Hattendorf, M. Juchli, F. Krumeich, C. Ludwig, K. Prikopsky, M. Rossier, D. Saner, A. Sigg, S. Hellweg, D. Günther, W. J. Stark, Nat. Nanotechnol. 2012, 7, 520. [311] V. C. Sanchez, J. R. Pietruska, N. R. Miselis, R. H. Hurt, A. B. Kane, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2009, 1, 511. [312] L. Dal Bosco, G. E. Weber, G. M. Parfitt, A. P. Cordeiro, S. K. Sahoo, C. Fantini, M. C. Klosterhoff, L. A. Romano, C. A. Furtado, A. P. Santos, J. M. Monserrat, D. M. Barros, PLOS One 2015, 10, e0129156. [313] T. Akagi, M. Higashi, T. Kaneko, T. Kida, M. Akashi, Biomacromolecules 2006, 7, 297. [314] N. Kamaly, B. Yameen, J. Wu, O. C. Farokhzad, Chem. Rev. 2016, 116, 2602. [315] A. A. Shvedova, N. Yanamala, E. R. Kisin, A. V. Tkach, A. R. Murray, A. Hubbs, M. M. Chirila, P. Keohavong, L. P. Sycheva, V. E. Kagan, V. Castranova, Am. J. Physiol.: Lung Cell. Mol. Physiol. 2014, 306, L170. [316] S. Seré, B. D. Roo, M. Vervaele, S. V. Gool, P. Sandra, J. W. Seo, J.-P. Locquet, J. Nanomater. 2018, 2018, 1. [317] I. I. Vlasova, A. A. Kapralov, Z. P. Michael, S. C. Burkert, M. R. Shurin, A. Star, A. A. Shvedova, V. E. Kagan, Toxicol. Appl. Pharmacol. 2016, 299, 58. [318] G. Morose, J. Cleaner Prod. 2010, 18, 285. [319] B. L. Allen, P. D. Kichambare, P. Gou, I. I. Vlasova, A. A. Kapralov, N. Konduru, V. E. Kagan, A. Star, Nano Lett. 2008, 8, 3899. [320] Y. Zhao, B. L. Allen, A. Star, J. Phys. Chem. A 2011, 115, 9536. [321] G. P. Kotchey, B. L. Allen, H. Vedala, N. Yanamala, A. A. Kapralov,\nY. Y. Tyurina, J. Klein-Seetharaman, V. E. Kagan, A. Star, ACS Nano 2011, 5, 2098.\n[322] V. E. Kagan, N. V. Konduru, W. Feng, B. L. Allen, J. Conroy, Y. Volkov, I. I. Vlasova, N. A. Belikova, N. Yanamala, A. Kapralov, Y. Y. Tyurina, J. Shi, E. R. Kisin, A. R. Murray, J. Franks, D. Stolz, P. Gou, J. Klein-Seetharaman, B. Fadeel, A. Star, A. A. Shvedova, Nat. Nanotechnol. 2010, 5, 354.\nAdv. Mater. 2019, 1805391\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1805391 (33 of 33)\n[323] K. Bhattacharya, R. El-Sayed, F. T. Andón, S. P. Mukherjee, J. Gregory, H. Li, Y. Zhao, W. Seo, A. Fornara, B. Brandner, M. S. Toprak, K. Leifer, A. Star, B. Fadeel, Carbon 2015, 91, 506. [324] R. Kurapati, J. Russier, M. A. Squillaci, E. Treossi, C. Ménard-Moyon, A. E. Del Rio-Castillo, E. Vazquez, P. Samorì, V. Palermo, A. Bianco, Small 2015, 11, 3985. [325] A. R. Sureshbabu, R. Kurapati, J. Russier, C. Ménard-Moyon, I. Bartolini, M. Meneghetti, K. Kostarelos, A. Bianco, Biomaterials 2015, 72, 20. [326] X. Li, J. Kim, J. Yoon, X. Chen, Adv. Mater. 2017, 29, 1606857. [327] S. Zhang, R. Geryak, J. Geldmeier, S. Kim, V. V. Tsukruk, Chem. Rev. 2017, 117, 12942. [328] F. Gao, W. Zheng, L. Gao, P. Cai, R. Liu, Y. Wang, Q. Yuan, Y. Zhao, X. Gao, Adv. Healthcare Mater. 2017, 6, 1601453. [329] Y. P. Qin, J. Chen, Y. Bi, X. H. Xu, H. Zhou, J. M. Gao, Y. Hu, Y. L. Zhao, Z. F. Chai, Acta Biomater. 2015, 17, 201. [330] Y.-S. Kwon, S. J. Jang, Y. I. Yoon, H.-S. Cho, H. J. Lee, Y.-S. Cho, H. S. Shin, T.-J. Yoon, Part. Part. Syst. Charact. 2016, 33, 242. [331] J. F. Quinn, M. R. Whittaker, T. P. Davis, Polym. Chem. 2017, 8, 97. [332] M. Martínez-Carmona, A. Baeza, M. A. Rodriguez-Milla,\nJ. García-Castro, M. Vallet-Regí, J. Mater. Chem. B 2015, 3, 5746. [333] L. Feng, K. Li, X. Shi, M. Gao, J. Liu, Z. Liu, Adv. Healthcare Mater. 2014, 3, 1261. [334] L. Yan, Y.-N. Chang, L. Zhao, Z. Gu, X. Liu, G. Tian, L. Zhou,\nW. Ren, S. Jin, W. Yin, H. Chang, G. Xing, X. Gao, Y. Zhao, Carbon 2013, 57, 120. [335] C. L. Weaver, J. M. LaRosa, X. Luo, X. T. Cui, ACS Nano 2014, 8, 1834. [336] R. Dou, Z. Du, T. Bao, X. Dong, X. Zheng, M. Yu, W. Yin, B. Dong, L. Yan, Z. Gu, Nanoscale 2016, 8, 11531. [337] L. Yan, Y. Chang, W. Yin, G. Tian, L. Zhou, X. Liu, G. Xing, L. Zhao, Z. Gu, Y. Zhao, Biomater. Sci. 2014, 2, 1412. [338] Y. Cho, Y. Choi, Chem. Commun. 2012, 48, 9912. [339] S. Li, Q. Jiang, S. Liu, Y. Zhang, Y. Tian, C. Song, J. Wang, Y. Zou,\nG. J. Anderson, J.-Y. Han, Y. Chang, Y. Liu, C. Zhang, L. Chen, G. Zhou, G. Nie, H. Yan, B. Ding, Y. Zhao, Nat. Biotechnol. 2018, 36, 258.\n[340] Q. Zhou, L. Zhang, T. Yang, H. Wu, Int. J. Nanomed. 2018, 13, 2921.\n[341] W. Fan, B. C. Yung, X. Chen, Angew. Chem. 2018, 130, 8516. [342] K. Bauri, M. Nandi, P. De, Polym. Chem. 2018, 9, 1257. [343] Y. Deng, J. Ling, M.-H. Li, Nanoscale 2018, 10, 6781. [344] M. L. Etheridge, S. A. Campbell, A. G. Erdman, C. L. Haynes, S. M. Wolf, J. McCullough, Nanomedicine 2013, 9, 1. [345] Y. Min, J. M. Caster, M. J. Eblan, A. Z. Wang, Chem. Rev. 2015, 115, 11147. [346] P. Satalkar, B. S. Elger, P. Hunziker, D. Shaw, Nanomedicine 2016, 12, 893. [347] J. M. Caster, A. N. Patel, T. Zhang, A. Wang, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2017, 9, e1416. [348] V. Sainz, J. Conniot, A. I. Matos, C. Peres, E. Zupanǒiǒ, L. Moura,\nL. C. Silva, H. F. Florindo, R. S. Gaspar, Biochem. Biophys. Res. Commun. 2015, 468, 504.\n[349] D. Bobo, K. J. Robinson, J. Islam, K. J. Thurecht, S. R. Corrie, Pharm. Res. 2016, 33, 2373. [350] C. L. Ventola, Pharm. Ther. 2017, 42, 742. [351] A. N. Gordon, M. Tonda, S. Sun, W. Rackoff, Gynecol. Oncol. 2004, 95, 1. [352] S. K. Samal, M. Dash, S. Van Vlierberghe, D. L. Kaplan, E. Chiellini,\nC. van Blitterswijk, L. Moroni, P. Dubruel, Chem. Soc. Rev. 2012, 41, 7147.\n[353] S. J. Soenen, W. J. Parak, J. Rejman, B. Manshian, Chem. Rev. 2015, 115, 2109. [354] M. F. Bellin, C. Roy, K. Kinkel, D. Thoumas, S. Zaim, D. Vanel, C. Tuchmann, F. Richard, D. Jacqmin, A. Delcourt, E. Challier, T. Lebret, P. Cluzel, Radiology 1998, 207, 799. [355] M. Thill, A. Kurylcio, R. Welter, V. van Haasteren, B. Grosse, G. Berclaz, W. Polkowski, N. Hauser, Breast 2014, 23, 175. [356] A. Jordan, R. Scholz, P. Wust, H. Fähling, J. Krause, W. Wlodarczyk, B. Sander, T. Vogl, R. Felix, Int. J. Hyperthermia 1997, 13, 587. [357] G. M. Chertow, P. D. Mason, O. Vaage-Nilsen, J. Ahlmén, Nephrol., Dial. Transplant. 2004, 19, 1571. [358] B. V. Beers, C. c. Grandin, J. Jamart, R. Demeure, T. F. Jacobsen, J. Pringot, Eur. J. Radiol. 1992, 14, 252. [359] J. Scheidler, A. F. Heuck, W. Meier, M. F. Reiser, J. Magn. Reson. Imaging 1997, 7, 1027. [360] W. K. Johnson, C. Stoupis, G. M. Torres, E. B. Rosenberg, P. R. Ros, Magn. Reson. Imaging 1996, 14, 43.\nAdv. Mater. 2019, 1805391"
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "H. Lin", "Y. Chen", "J. Shi" ],
      "venue" : "Soc. Rev. 2018, 47",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 1938
    }, {
      "title" : "Figure 15",
      "author" : [ "B. Pelaz", "C. Alexiou", "R.A. Alvarez-Puebla", "F. Alves", "A.M. Andrews", "S. Ashraf", "L.P. Balogh", "L. Ballerini", "A. Bestetti", "C. Brendel", "S. Bosi", "M. Carril", "W.C.W. Chan", "C. Chen", "X. Chen", "X. Chen", "Z. Cheng", "D. Cui", "J. Du", "C. Dullin", "A. Escudero", "N. Feliu", "M. Gao", "M. George", "Y. Gogotsi", "A. Grünweller", "Z. Gu", "N.J. Halas", "N. Hampp", "R.K. Hartmann", "M.C. Hersam", "P. Hunziker", "J. Jian", "X. Jiang", "P. Jungebluth", "P. Kadhiresan", "K. Kataoka", "A. Khademhosseini", "J. Kopeček", "N.A. Kotov", "H.F. Krug", "D.S. Lee", "C.-M. Lehr", "K.W. Leong", "X.-J. Liang", "M. Ling Lim", "L.M. Liz-Marzán", "X. Ma", "P. Macchiarini", "H. Meng", "H. Möhwald", "P. Mulvaney" ],
      "venue" : "Superparamagnetic iron oxide NPs as an oral contrast agent in gastrointestinal MR imaging. a) Axial oral contrast-enhanced computed tomography ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 1805
    }, {
      "title" : "Towards Efficient Designing of Safe Nanomaterials: Innovative Merge of Computational Approaches and Experimental Techniques (Eds",
      "author" : [ "C.P. Roca", "R. Rallo", "A. Fernandez", "F. Giralt" ],
      "venue" : "Royal Society of Chemistry,",
      "citeRegEx" : "58",
      "shortCiteRegEx" : "58",
      "year" : 2012
    }, {
      "title" : "Nano Lett",
      "author" : [ "C.Y. Chen", "G.M. Xing", "J.X. Wang", "Y.L. Zhao", "B. Li", "J. Tang", "G. Jia", "T.C. Wang", "J. Sun", "L. Xing", "H. Yuan", "Y.X. Gao", "H. Meng", "Z. Chen", "F. Zhao", "Z.F. Chai", "X.H. Fang" ],
      "venue" : "2005, 5",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2050
    }, {
      "title" : "Nanoscale Fabrication, Optimization, Scale-Up and Biological Aspects of Pharmaceutical Nanotechnology",
      "author" : [ "B. Dogan-Topal", "B. Uslu", "S.A. Ozkan" ],
      "venue" : "UK 2018,",
      "citeRegEx" : "144",
      "shortCiteRegEx" : "144",
      "year" : 2018
    }, {
      "title" : "Toxicol. Environ. Mutagen",
      "author" : [ "L.M. Sargent", "A.F. Hubbs", "S.H. Young", "M.L. Kashon", "C.Z. Dinu", "J.L. Salisbury", "S.A. Benkovic", "D.T. Lowry", "A.R. Murray", "E.R. Kisin", "K.J. Siegrist", "L. Battelli", "J. Mastovich", "J.L. Sturgeon", "K.L. Bunker", "A.A. Shvedova", "S.H. Reynolds", "Mutat. Res", "Genet" ],
      "venue" : null,
      "citeRegEx" : "146",
      "shortCiteRegEx" : "146",
      "year" : 2012
    }, {
      "title" : "ACS Nano 2013",
      "author" : [ "Y. Wang", "K.C.L. Black", "H. Luehmann", "W. Li", "Y. Zhang", "X. Cai", "D. Wan", "S.-Y. Liu", "M. Li", "P. Kim", "Z.-Y. Li", "L.V. Wang", "Y. Liu", "Y. Xia" ],
      "venue" : "7",
      "citeRegEx" : "229",
      "shortCiteRegEx" : null,
      "year" : 2068
    }, {
      "title" : "Eur",
      "author" : [ "S. Kohei", "T. Kimikazu", "T. Kosuke", "Y. Tomoyoshi", "H. Hiroshi", "K. Hidehiro" ],
      "venue" : "J. Inorg. Chem. 2010",
      "citeRegEx" : "235",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Chem",
      "author" : [ "C. Gunawan", "M. Lim", "C.P. Marquis", "R. Amal", "J. Mater" ],
      "venue" : "B 2014, 2",
      "citeRegEx" : "256",
      "shortCiteRegEx" : null,
      "year" : 2060
    }, {
      "title" : "J",
      "author" : [ "S. Salmaso", "P. Caliceti" ],
      "venue" : "Drug Delivery 2013",
      "citeRegEx" : "260",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Parambath, in Engineering of Biomaterial for Drug Delivery Systems: Beyond Polyethylene Glycol (Ed: A",
      "author" : [ "A.N. Hadjesfandiari" ],
      "venue" : null,
      "citeRegEx" : "290",
      "shortCiteRegEx" : "290",
      "year" : 2018
    }, {
      "title" : "J",
      "author" : [ "S. Seré", "B.D. Roo", "M. Vervaele", "S.V. Gool", "P. Sandra", "J.W. Seo", "J.-P. Locquet" ],
      "venue" : "Nanomater. 2018",
      "citeRegEx" : "316",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "ACS Nano 2011",
      "author" : [ "G.P. Kotchey", "B.L. Allen", "H. Vedala", "N. Yanamala", "A.A. Kapralov", "Y.Y. Tyurina", "J. Klein-Seetharaman", "V.E. Kagan", "A. Star" ],
      "venue" : "5",
      "citeRegEx" : "321",
      "shortCiteRegEx" : null,
      "year" : 2098
    } ],
    "referenceMentions" : [ {
      "referenceID" : 2,
      "context" : "Nanoinformatics, an emerging field of nanomedicine, involves the management of data derived from study on nanomaterials and their biomedical applications, followed by the integration and analysis of such data with computational algorithms to identify important nanomedicine design parameters as guidance for computational and experimental nanomedical research.[58,59] For example, several computational models have already been developed to study the fundamental properties and biological behaviors of nanomedicines, such as drug encapsulation, delivery and release,[60,61] as well as their biological effects on the cells and tissues.",
      "startOffset" : 360,
      "endOffset" : 367
    }, {
      "referenceID" : 5,
      "context" : "disruption, DNA fragmentation, and subsequent cellular aneuploidy.[146] CdTe QDs with the diameter of 3.",
      "startOffset" : 66,
      "endOffset" : 71
    }, {
      "referenceID" : 6,
      "context" : "reported that gold nanohexapods as PTT agents showed higher cellular uptake and antitumor efficacy but lower cytotoxicity than gold nanorods and nanocages.[229] These above studies clearly demonstrate that the optimization of the size and structure of nanomaterial-based agents is critical for the development of safe nanomedicines.",
      "startOffset" : 155,
      "endOffset" : 160
    }, {
      "referenceID" : 7,
      "context" : "In fact, HfO2 NPs have been successfully tested as promising radiosensitizers to enhance radiotherapy,[233] Gd2O3 NPs as contrast agents for CT and MR imaging,[234] Y2O3 NPs as upconversion fluorescence probes for bioimaging and biosensing,[235,236] and SiO2 NPs as nanocarriers for drug delivery.",
      "startOffset" : 240,
      "endOffset" : 249
    }, {
      "referenceID" : 0,
      "context" : "This makes surface defects of nanomaterials a favored medium for chemical, biological, and toxicological processes at the bio-nano interface.[8] Muller et al.",
      "startOffset" : 141,
      "endOffset" : 144
    }, {
      "referenceID" : 8,
      "context" : "These bio-physicochemical interactions at the bionano interface may induce structural and functional alterations to the biomolecules and cause unpredictable adverse health effects,[254,255] as well as heavily affecting the blood circulation time of nanomedicines.[256] For example, ZnO NPs with the diameter of ≈20 nm could selectively interact with β-galactosidase to inhibit their catalytic activity.",
      "startOffset" : 263,
      "endOffset" : 268
    }, {
      "referenceID" : 9,
      "context" : "some proteins have been developed for stealth coatings.[260] Benefiting from its neutral electricity, flexibility, and hydrophilic properties, polyethylene glycol (PEG) with linear and branched structures is the most widely used “stealth” polymer for nanosurface modification.",
      "startOffset" : 55,
      "endOffset" : 60
    }, {
      "referenceID" : 10,
      "context" : "[289] Biodegradable polymers including chitosan, poly(phosphoester) and polyglutamic acid have achieved great attention for medical applications since they could be enzymatically hydrolyzed and degraded into nontoxic small molecules and do not accumulate in the body.[290] For example, hydroxyethyl starch (HES), a starch derivative that can be decomposed in vivo by amylases, has been applied to fabricate biodegradable nanocarriers with low unspecific interactions with biological components and prolonged circulation time in blood.",
      "startOffset" : 267,
      "endOffset" : 272
    }, {
      "referenceID" : 11,
      "context" : "b–d) Adapted with permission.[316] Copyright 2018, Hindawi.",
      "startOffset" : 29,
      "endOffset" : 34
    }, {
      "referenceID" : 11,
      "context" : "demonstrated that mesoporous silica NPs functionalized with triethanolamine (TEA) degraded much faster than both carboxylated and nonfunctionalized NPs, with their degradation rate showing a TEA dose-dependent manner[316] (Figure 10b–d).",
      "startOffset" : 216,
      "endOffset" : 221
    }, {
      "referenceID" : 12,
      "context" : "Later, other carbon-based nanomaterials including GO and MWCNTs have also been demonstrated as degradable by HRP and H2O2,,([320,321]) and SWCNTs have been reported to be degraded by other mammalian peroxidases with the catalytic heme active site in the presence of H2O2 or halide ions.",
      "startOffset" : 124,
      "endOffset" : 133
    }, {
      "referenceID" : 12,
      "context" : "g–k) Adapted with permission.[321] Copyright 2011, American Chemical Society.",
      "startOffset" : 29,
      "endOffset" : 34
    } ],
    "year" : 2019,
    "abstractText" : "Dr. L. Yan, Dr. F. Zhao, Dr. J. Wang, Dr. Y. Zu, Prof. Z. Gu, Prof. Y. Zhao CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety Nanoscience National Center for Nanoscience and Technology of China Beijing 100190, China E-mail: zjgu@ihep.ac.cn; zhaoyl@nanoctr.cn Dr. L. Yan, Dr. F. Zhao, Dr. Y. Zu, Prof. Z. Gu, Prof. Y. Zhao CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety Institute of High Energy Physics Chinese Academy of Sciences Beijing 100049, China Prof. Z. Gu, Prof. Y. Zhao College of Materials Science and Optoelectronic Technology University of Chinese Academy of Sciences Beijing 100049, China Prof. Y. Zhao CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing 100190, China The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201805391.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}